Browse Author: admin

Top Biosimilars Conference in 2018, Biosimilars 2018, Largest Biologics Conferences, USA, Europe, Asia, pharmaceutical conference.#Pharmaceutical

Biologics and Biosimilars

Theme: Emerging Trends in Biosimilars Approvals, Market and Pricing

Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Recommended Global Pharma Marketing & Industry Conferences

USA Americas
Europe UK
Asia Pacific Middle East

Biosimilars 2018

To Collaborate Scientific Professionals around the World

Conference Date October 24-25, 2018

For Sponsors Exhibitors

Useful Links

Past Conference Report

Supported By

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by

Quick Links

  • Abstracts Submission

Conference Highlights

Conferences By Continents

USA Americas

Asia-Pacific Middle East

Europe UK

Medical Clinical Conferences

Conferences By Subject

Mail us at

” class=”wrap-link”> Kiara Dcruize

Contact us at

Pharmaceutical conference

13 th International Conference on Biologics and Biosimilars

Please leave a message and someone will get back to you shortly.

  • Australia – Toll Free Numbers – 1-800-651-097
  • France – Toll Free Numbers – 0805-080048
  • Hyderabad – Toll Free Numbers -91-40-71279012
  • Hyderabad – Toll Free Numbers -91-40-71279013
  • UK – 0-800-014-8923
  • Los Angeles Downtown – 1-213-233-9462
  • USA/Canada – 1-888-843-8169

Be a member and support us

Follow us

Authorization Policy

By registering for the conference you grant permission to Conferenceseries Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.





Torrent Pharmaceuticals Limited, value pharmaceuticals.#Value #pharmaceuticals

value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals

Value pharmaceuticals Value pharmaceuticals

and creates leaders. Inspiring work culture, competitive rewards





MBS Pharmacy Full Service Pharmacy Serving The Long Term Care Industry, pharmacy industry.#Pharmacy #industry

The MBS Pharmacy Difference

Our Values and Guiding Principles.

Our associates live the Golden Rule. Our associates demonstrate commitment to coaching, mentoring, and developing other leaders.

Our associates at MBS Pharmacy hold themselves to the same standard of performance expected of others.

Our associates at MBS Pharmacy focus on the customer impact in operational decision making and planning everyday.

Our associates show willingness to make decisions, acknowledge mistakes and welcome change as an opportunity.

Provide the best customer service to the long term care industry.

Optimize quality of care for long term residents through medication management.

Provide thorough training and ongoing consultation with facility staff members.

Our goals is to ensure cost containment and operational efficiency.

Our Mission

MBS Pharmacy goal is to be the industry leader in long term care by which all standards of service are defined. Our commitment is to provide the best service possible to our customers and their residents by ensuring the highest standards of safety and accuracy while maintaining cost-effectiveness. We strive for excellence both internally with our staff and externally with those entrusted to our care. Our mission is to provide the best healthcare services for our patients and a sense of pride and purpose for our Associates.

Company History

MBS Pharmacy was founded in February 2004 as a closed door pharmacy specializing in providing medications to patients in long term care facilities. We currently service the entire state of Texas and delivery to each location daily. We are independently owned which allows us to be nimble and flexible to meet the needs of our customers. We pride ourselves on filling prescriptions accurately and in a timely manner to meet the needs of our residents. As patients transition from a long term care environment back to their communities, MBS Pharmacy has a Meds 2 Home program to dispense medications upon discharging to improve medication compliance and reduce readmissions back to the hospital or long term care facility.

Our Services

We specialize in providing high-quality, personalized services with an attention to detail and accuracy.

Care Program

We provide an excellent care program for each resident in every facility and provides home medication as well.

Pharmacy

Comprehensive database with a detailed medication history for each resident in every facility we serve.

Online Payments

We provide the ability to make secure online payments for pharmacy bills for all residents in every facility.

Reporting

We provide an excellent reporting system that reports financial data for every facility we serve.





Atlanta Job Recruiters Employment for Workers over 50 – Silver Staffing, pharmaceutical sales recruiters.#Pharmaceutical #sales

pharmaceutical sales recruiters

Pharmaceutical sales recruiters

Pharmaceutical sales recruiters

Welcome to SilverStaffing.com!

you have come to the right place!

Pharmaceutical sales recruiters

. our technology and resources for recruiters and job . with a more positive online

employment experience . Atlanta job seekers: AtlantaRecruiter.com was designed to .

. job seekers and increase awareness of your employment brand . and receive resumes

directly from Atlanta job seekers . Locate job seekers by keyword or industry, and .

. Atlanta Employment and Jobs Guide Atlanta employment resources, including staffing

agencies, recruiters, and Atlanta job boards and classifieds. .

. seeker. The Atlanta Job Bank One of Atlanta’s best employment

resources to be found on the Internet. Atlanta .

. jobs, jobs in atlanta, pharmaceutical, representative, headhunter, research, employment,

pharmacuetical, pharmaceutical sales, resumes, sales recruiters, career .

Atlanta job search and Atlanta employment search as well as Atlanta recruiters listings

resume tutorial US training posting resume job market recruiter agency .

www.resumecourier.ca/EmploymentDirectory/ Recruiters/Georgia/Atlanta.asp – 79k – Cached – Similar pages

. Atlanta, jobs, careers, employment, help wanted, Atlanta help wanted, Atlanta

. Post your Resume and Search Jobs Free. Atlanta job listings,Atlanta jobs,Atlanta

help wanted, Atlanta recruiters,Atlanta employers,resume post for Atlanta job. .

. Jobs in Georgia, Atlanta, Hawaii Executive Jobs in . headhunter recruiter, executivesonly,

employment headhunter, high . executive recruitment, job search executive .

. is looking for a permanent placement recruiter for it’s Food, Beverage, Manufacturing

permanent placement . Job Status: Full Time. The Judge Group, US-GA-Atlanta. .





Pharmaceuticals, An Open Access Pharmaceutical Sciences Journal from MDPI, value pharmaceuticals.#Value #pharmaceuticals

Pharmaceuticals — Open Access Pharmaceutical Sciences Journal

  • Open Access – free for readers, with article processing charges (APC) paid by authors or their institutions.
  • High visibility: citations available in PubMed, full-text archived in PubMed Central. Covered by Embase and Scopus. To be indexed in the Emerging Sources Citation Index – ESCI (Web of Science) from Vol. 10 (2017).
  • CiteScore: 4.90, based on citations in 2016 to articles published 2013-2015,
  • Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 27 days after submission; acceptance to publication is undertaken in 5 days (median values for papers published in this journal in first half of 2017).
  • Testimonials:See what our authors say about Pharmaceuticals

Latest Articles

Value pharmaceuticals

100 nm diameter nanoparticles in aqueous media and can encapsulate doxorubicin (DOX), a well-known anti-cancer drug, and chloroquine (CQ), a known chemosensitizer with arising potential in anticancer medication. The anticancer activity of this system against two aggressive DOX-resistant human prostate adenocarcinoma cell lines and in in vivo animal studies was assessed. The co-administration of encapsulated DOX and CQ leads to improved cell proliferation inhibition at extremely low DOX concentrations (0.25 μΜ). In vivo experiments against DU145 human prostate cancer cells grafted on immunodeficient mice resulted in tumor growth arrest during the three-week administration period and no pervasive side effects. The findings put forward the potential of such targeted low dose combination treatments as a therapeutic scheme with minimal adverse effects. Full article

Value pharmaceuticals





Training UK Physicians: Physician to Pharma: Only Medics, pharma training.#Pharma #training

Training for UK Physicians – Physician2Pharma

33 Blagrave Street

Keep connected join the Only Medics Network here.

Pharma training Pharma training Pharma training Pharma training Pharma training Pharma training Pharma training Pharma training Pharma training

Specialist Sectors

Training for entry level pharmaceutical physicians – Physician2Pharma

Physician2Pharma workshops are free 1 day training workshops developed and organised by Only Medics. Attendance at the workshop is by invitation following a detailed screening process. The workshops are also attended by industry professionals, some of whom are actively recruiting. Delegates will be expected to have already researched roles for physicians and be committed to making a move into industry without delay.

Receive independent, targeted career advice

Learn more about the processes of Clinical Research, Medical Affairs and Pharmacovigilance

Learn about interview techniques and how to be successful when applying for roles

Take part in practical exercises about working in the industry

Receive a presentation folder packed with information about the pharmaceutical industry

The day includes presentations by experienced industry physicians and HR professionals. The day focuses on educating new-to-medics as well as testing their skills in front of hiring managers and industry professionals.

HR professionals and medics from pharmaceutical companies are invited to attend as observers. They have opportunity to see how the candidates perform and interact at the workshop rather than hiring on the basis of interviews alone. During breaks and over lunch, delegates mingle with the industry professionals in a relaxed and informal environment and discuss points of interest.

The next Physician2Pharma event

To apply to attend the next workshop, please call our consultants on +44(0)118 952 2799 and confirm your interest when registering with us. We will then contact you to discuss your career aspirations in more detail.

Please note that candidates for Physician2Pharma workshops must have:

Full GMC registration or an equivalent eligible for full GMC registration

At least 2 years post registration in recognised training rotations in the UK

Good evidence of prior research into roles in the pharmaceutical industry

Motivation and commitment to make a career transition into the industry

Excellent communication skills

Therapeutic expertise in Oncology, Haematology, Diabetes, Metabolic Disease, Endocrinology, GI, Infectious Diseases, Virology, CNS, Cardiology, Anaesthesia, Rheumatology or Respiratory medicine is a distinct advantage

For a role in Clinical Research, prior involvement in clinical trials; either as an investigator or sub-investigator, is important.

Comments from the previous Physician2Pharma training workshops:

Excellent speakers, valuable information and insight to the pharmaceutical industry

“I found myself thinking about entering pharma for quite some time before I finally plucked up the courage to make those first calls, and despite having made the decision, I found myself still in need of some reassurance, the so called best practice evidence . What I found so wonderful about the physician to pharma day is that it was full of people just like me those that were also pondering over the same decisions and anxieties (the what if s ) and those that had already taken the leap and navigated their way into successful and rewarding careers as medics in pharma.

The day was structured so well, on so many levels; it gave me the opportunity on a personal level to engage with those who understood my motivations, my anxieties, the complexities involved with the process of moving into pharma. On a professional level, the workshop sessions, mentored by industry medics replicated the work we could expect to be doing in our future roles as Medical Advisors, being highly engaging, interesting, stimulating and reassuring all at the same time.

I thoroughly enjoyed the day and could not recommend it highly enough to anybody seriously considering entering pharma. I learnt so much in one day, through the structured activities and networking with the other medics there that it really was invaluable. To my surprise, the icing on the cake was a phone call the following morning, which was followed up by an interview and job offer within the week. 3 months into my new job, there is no looking back, no regrets, a job I love, in a great company.”

“As a hiring manager, I found the Physician to Pharma event a fantastic opportunity to meet with around 20 candidates over the course of a full day and was able to understand their skills and background together with their motivations for joining industry.

There were plenty of opportunities for them to ask questions to the hiring managers and I think the candidates also got a really good feel for what its like making the transition from clinical medicine into industry and whether it was right for them. I really enjoyed meeting them all and there was a huge amount of talent in the room – the candidates had been well screened by Only Medics. On the day, for me, there was one stand out candidate. I hired her within the week”

“Just a short note to thank you for inviting me to the excellent workshop today. I found it inspiring, well-organised and very informative.”

“One of the most enjoyable days I’ve had in a while! Excellent candidates, enthusing presentations and just great, open-minded practical advice from someone who really understands medical roles and our industry.”

“I will not lie to you, prior to attending the workshop I had spoken with another recruitment company and as you know my CV was available on other websites so I subsequently received several calls from other companies. That being said, none impressed me as much as Only Medics and I fully intend to deal with you exclusively. I thank you once again for the opportunity to attend the workshop and look forward to speaking to you again in due course.”





Phoenix, Investing in Advanced Materials, phoenix pharmaceuticals.#Phoenix #pharmaceuticals

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advanced Materials Venture Capital

Phoenix pharmaceuticals

We invest in start-up teams developing breakthrough advanced materials innovations. Our investment strategy is predicated on assisting entrepreneurs with customer and supply chain business development and providing strategic and operational support.

Advances in underlying materials and processes are revolutionizing almost every industry.

We look for transformative Advanced Materials innovations, including novel engineered materials, new device architectures, and advanced process technologies and tools. We invest in innovations that enable entirely new products, dramatic performance improvements of existing products, enhanced-efficiency, and/or greener manufacturing processes for major industries such as Consumer Electronics, Drug Delivery, Chemicals, Energy Generation, Energy Storage, Solar, Water, and Building Materials to name a few.

Estimates of the industrial impact of Advanced Materials innovations over the next decade exceed $3 Trillion.

Phoenix pharmaceuticals

Phoenix pharmaceuticals

Reinventing Venture Capital

Advanced Materials is a significant yet under-served area of innovation by venture capitalists. It requires specialized knowledge of materials sciences, industrial value chains, and business models. At PVP, we have developed a unique value-add approach based on successfully founding, operating, and investing in advanced material start-ups over the past 30 years.

Our Team

We understand that teams are the most important ingredient in any start-up. Meet our team. We have an unparalleled success rate, with some failures too. We are constantly learning and enjoy working with entrepreneurs.

Phoenix pharmaceuticals

John T Chen

Phoenix pharmaceuticals

Zach Jonasson

Phoenix pharmaceuticals

Nobuyuki Kambe

Phoenix pharmaceuticals

Avinash Kant

Phoenix pharmaceuticals

Frank Levinson

Phoenix pharmaceuticals

Srinivas Rao

Phoenix pharmaceuticals

David Soane

Phoenix pharmaceuticals

Jennifer Wang

Strategic Partners

PVP enjoys valuable strategic relationships with a diversified consortium of industry leading corporations. Our S trategic P artners , several of which have also elected to be Strategic Limited Partners in one or more of our Funds, have a combined market capitalization exceeding $380 Billion and represent complimentary industry verticals, value chain positions, and geographic concentrations. These partnerships help define key industry needs and market opportunities. Our portfolio companies enjoy access to this deep set of potential customer and supply chain partner relationships. And, we make business development introductions between our partners and promising start-ups, even if the start-up is not an investment fit for our funds.

Industrial Scientific Advisory Board

PVP draws from a talented group of Industrial Scientific Advisors who have expertise in advanced materials R D and commercialization across multiple industries, including speciality chemicals, high performance materials, photonics, coatings, building materials, pharmaceuticals, electronics, energy, QC tools, and medical devices.





Medical Marijuana Could Help Arizona Senator John McCain Glioblastoma, Phoenix New Times, phoenix pharmaceuticals.#Phoenix #pharmaceuticals

Connect. Discover. Share.

Phoenix pharmaceuticals

Get the most out of your experience with a personalized all-access pass to everything local on events, music, restaurants, news and more.

Enter your email or sign up with a social account to get started

Already registered? Login

Don’t have an account yet?

Recommended For You

Phoenix pharmaceuticals

How Medical Marijuana Could Help John McCain With Glioblastoma

Should U.S. Senator John McCain get an Arizona medical-marijuana card, now that he’s been diagnosed with glioblastoma?

He qualifies for the right to possess and use cannabis under Arizona law, and cannabis is well-known for its effectiveness in helping patients cope with chemotherapy.

Related Stories

Marijuana Is Real Medicine for a Long List of Ills

‘Til Death Do Us Part: They Got Married. Then Everything Changed

Popular Edible Cannabis Bhang Bars Are Leaving Arizona for Now, but the Company Vows to Return

His support of the program and medical marijuana in general also could give a boost to research, some of which could lead to cannabis-based treatments for glioblastoma.

“If I hung up and I had brain cancer, I would explore a list of treatments and products” related to cannabis, said Jahan Marcu, a researcher and activist who works as a science advisor and auditor for Americans for Safe Access, an advocacy group in New York City.

Phoenix pharmaceuticals

Marcu was the lead researcher in a 2010 study that revealed how cannabis held great promise for glioblastoma treatment.

According to an article about the study published in the Journal of Molecular Cancer Therapeutics, the combinations of the cannabis compounds THC and cannabindiol (CBD) “may represent an improvement for the treatment of patients with glioblastoma and perhaps additional cancers. It is also possible that other constituents of C. sativa that are not structurally related to cannabinoids could improve antitumor activity when combined.”

Later studies have claimed similar results.

“But this is not to say if you could smoke cannabis it will cure your brain cancer,” Marcu said in an interview on Thursday. “What we know is that, in animal studies, for rats and mice, we can cure cancer with cannabis or cannabis combined with chemotherapy.”

Experiments involving direct injections on living human brains haven’t yet been tried, he said, adding that federal restrictions on cannabis studies at all levels hurt scientific progress.

However, that’s not to say McCain can’t benefit from cannabis right away. As a statement from his office revealed this week, he’ll be entering chemotherapy treatment.

In February, GW Pharmaceuticals, a British company striving to mimic cannabinoids with synthetic medicines, announced that its research had shown that THC and CBD, in combination with a chemotherapy drug, had extended the lifespan of some glioblastoma patients.

“Moreover, the cannabinoid medicine was generally well-tolerated,” according to a statement by Professor Susan Short, the study’s lead investigator and a professor of cancer research at St James s University Hospital. “These promising results are of particular interest as the pharmacology of the THC:CBD product appears to be distinct from existing oncology medications and may offer a unique and possibly synergistic option for future glioma treatment.

Marcu does not advise smoking marijuana. But Marcu said he would consider inhaling a mist of concentrated-marijuana products, vaping it, or using a dissolvable oral product, to relieve chemo’s negative side effects of pain and nausea.

He would begin with a 50-50 mix of THC and CBD, (the latter compound is known to temper negative psychoactive effects of THC), and then “graduate to more THC” as he could tolerate it.

Phoenix pharmaceuticals

Marcu said that even doctors at the Veteran’s Administration, who are still prohibited from even recommending marijuana as a treatment for anything, could consider offering McCain the synthetic-THC drug Marinol, which was approved for use by the FDA in 1985.

McCain, given his grim diagnosis, could also simply try consuming as much marijuana as legally allowed in Arizona: As a state-authorized patient, he could buy up to 2.5 ounces every two weeks.





Herzlich Willkommen bei pharma-education! pharma-education, your success is our profession, pharma training.#Pharma #training

You are using an outdated browser.

Please upgrade your browser to improve your experience and reload.

Pharma training

Herzlich Willkommen bei pharma-education!

Wir sind Österreichs führendes Aus- und Weiterbildungs- sowie Personaldienstleistungs-Institut für Pharmareferenten und Medizinprodukteberater und als solches qualitätszertifiziert (EN ISO 9001:2008, Ö-CERT).

Laufend aktualisierte Infos hält der nachstehende Newsfeed für Sie bereit – einfach runterscrollen und durchklicken!

*Wir freuen uns auf Ihre Anforderung und bitten Sie uns im Sinne Ihrer optimalen Servicierung Ihre E-Mail-Adresse und/oder Anschrift (Kursort!) bekannt zu geben. Dankeschön!

Pharma training

Einmal mehr ein toller Prüfungserfolg.

Am 18. Oktober 2017 sind bei der mündlichen PRP gesamt acht Kandidat(inn)en von der schriftlichen Prüfung kommend angetreten. Sie alle konnten diesen finalen Part der staatlichen Pharmareferentenprüfung positiv absolvieren – sechs davon durfte pharma-education auf diese anspruchsvolle Prüfung vorbereiten ! Mit einer Quote von 75 % konnten wir somit einmal mehr unser Standing als Österreichs führendes Schulungsinstitut eindrucksvoll unter Beweis stellen!

Wir gratulieren unseren Schützlingen ganz, ganz herzlich!

Pharma training

Einladung zum Informationsabend Wien

Wir laden Sie herzlich zu unserem nächsten kostenfreien Informationsabend am Donnerstag, den 30 . November 2017 um 18.00 Uhr in unseren Wiener Seminarräumlichkeiten ein! Aus organisatorischen Gründen bitten wir Sie, uns Ihre Teilnahme vorab telefonisch oder per E-Mail bekannt zu geben.

Zwei Stunden stellen hinsichtlich der Dauer einen guten Richtwert dar. Je nach Anzahl der Fragen seitens der TeilnehmerInnen kann es auch schon mal um einiges länger werden – unsere GF Frau Nicole Kraule, MBA steht Ihnen an unseren Infoabenden jedenfalls mit Vergnügen zeitlich unbegrenzt zur Verfügung!

Pharma training

Stellenausschreibung:

Aktuell haben wir unter anderem folgende Position zu besetzen:

Der Dienstort befindet sich im Bezirk Mödling.

Neugierig? Klicken Sie HIER um näheres zu dieser Position und weiteren aktuellen Stellenausschreibungen zu erfahren!

Pharma training

Einladung zum Informationsabend Graz

Wir laden Sie herzlich zu unserem nächsten kostenfreien Informationsabend am 16. September 2017 in Graz ein. Dieser findet um 17.00 Uhr im Wolfühlhotel Novapark statt.

Aus organisatorischen Gründen bitten wir Sie, uns Ihre Teilnahme vorab telefonisch oder per E-Mail bekannt zu geben.

Pharma training

Hot Summer-News:

Das heurige zweite Prüfungshalbjahr der staatlichen Pharmareferentenprüfung naht mit Riesenschritten! Rüsten Sie sich für Ihren erfolgreichen Prüfungsantritt mit unserem Ende August stattfindenden Kleingruppentraining oder dem Super-Summary-Workshop Anfang September 2017!

Knackig intensive maximal effektive Tage!

Pharma training

Stellenausschreibung vom 08. August 2017

Aktuell haben wir unter anderem folgende Position zu besetzen:

für Teile Wiens und Niederösterreichs

Hier gilt es hochwertige Gesundheitsprodukte für ein bestens am Markt etabliertes Unternehmen zu repräsentieren und vertreiben.

Neugierig? Klicken Sie HIER um näheres zu dieser Position und weiteren aktuellen Stellenausschreibungen zu erfahren!

Pharma training

Aktuelles zur staatlichen Pharmareferentenprüfung

Der Abschluss des PHR-Prüfungsjahres 2015 naht mit großen Schritten – am 17. Dezember 2015 endet es mit dem mündlichen Teil der 339. Pharmareferentenprüfung im BMG.

Pharmareferent

Melden Sie sich gleich heute für einen Pharmareferenten-Workshop zur Vorbereitung auf die staatliche Pharmareferentenprüfung an.

Medizinprodukteberater

Melden Sie sich gleich heute für die Ausbildung zum zertifizierten Medizinprodukteberater an.

Aktuelle Karrierechancen

Jedenfalls einen Mausklick wert sind unsere attraktiven Stellenausschreibungen. Nutzen Sie Ihre Karrierechance!

Verkaufstraining

Ob in der Berufspraxis täglich dem Ziel der Verschreibung bzw. Bestellung folgend, oder aber das diesbezügliche Vermögen bereits zuvor beim potentiellen Arbeitgeber unter Beweis stellend – das Thema Verkauf ist dem Pharmareferenten und dem Medizinprodukteberater stets ganz, ganz nahe. Erwerben, trainieren bzw. festigen Sie Ihre Verkaufsskills mit unserem branchenfokussierten Verkaufstraining am 16. September 2016!

Ausbildungsförderung

Diverse Einrichtungen bieten Unterstützungen in der Höhe von 10-100% für Ihre berufliche Weiterbildung an.

Kostenvoranschlag

Wir stellen Ihnen gerne einen unverbindlichen Kostenvoranschlag für die Förderung Ihrer Aus- und Weiterbildung aus.

Seminarorte

Besuchen Sie unsere Aus- und Weiterbildungen an den Standorten Wien, Graz und Linz.





Clinical Trial Supply Europe 2018, arena pharmaceuticals.#Arena #pharmaceuticals

19th Annual Clinical Trial Supply Europe 2018

This year’s Clinical Trial Supply event builds on last year’s incredibly successful conference, and is to date our biggest conference yet. We have representatives from 6 of the top 10 pharmaceutical companies in Europe, who will be joined by leading biotech companies across the continent to jointly find solutions for your clinical trial supply problems and discuss changes in the industry.

As a streamed event this conference promises to address a larger variety of topics, with sessions covering all the essentials in clinical supply, from maximising forecasting software to patient centric strategies for supply chain and considering methods to achieve last mile delivery.

CTS Europe will take place in Milan on the 14th and 15th of March, 2018 and we are extremely excited to see you there!

Arena pharmaceuticals

Arena pharmaceuticals

Event News

What new sessions will the 2018 programme include?

This year’s conference promises to be our most exciting to date, with presentations from some of the industry’s top leading experts in the field of clinical trial supply. The following are a sample of what you will find in Milan in March:

Why Milan

After two successful years in Barcelona, CTS Europe is moving to the beautiful city of Milan, Italy’s manufacturing heartland. Since the late 1800s, Milan has been an important industrial and manufacturing centre, especially for the automotive industry, chemicals, machinery, pharmaceuticals and plastics, health and biotechnology and food beverage.

What to expect

The 2018 programme will host speakers from the likes of Sanofi, Teva, Merck, AstraZeneca, Janssen and GlaxoSmithKlein as well as a number of small to mid-sized biotechs like Spektrum Cannabis, 4SC AG or Shield Pharma. Through this two day conference, we will discoverthe practical benefits of e-labeling, while examining tech-driven ways to overcome issues and maximize current technologies to get the best result for your clinical supplies. There will also be stimulating roundtable discussions .

Moving forward, the Direct-to-Patient approach

It is commonly known that clinical trials are complex to operate, demanding protocols and patient recruitment are just some of the issues which many sponsors face today. With multiple complications, new initiatives are always being tested to minimize these discouraging features. One new initiative, the Direct-to-Patient method, has risen in the past decade.

The impact of EU 536/2014

Currently, conducting clinical trials within the European Union (EU) can be problematic, making the continent a less favorable location in comparison to other regions. To combat such issue, the EU has introduced a new regulation which replaces the European Clinical Trials Directive (2001/20/EC). The aim of EU 536/2014 is to create a more favorable environment for clinical trials, and to harmonise the requirements for performing clinical trials within the EU member states.

What did our 2017 audience have to say?

“Very well organized and in a excellent and charm environment. Most of the people were really interested in the presentations as well as participating in the interactive exercise. A really positive experience.” – Merck





Pharmaceutical conference, pharmaceutical conference.#Pharmaceutical #conference

pharmaceutical conference

Pharmaceutical conference

Pharmaceutical conference

  • Pharmaceutical conference
  • Pharmaceutical conference
  • 2017-07-01 APAC DA-EWG: HP has been Updated
  • 2017-05-01 The 6th APAC Meeting: Post-Meeting Follow-Up (Presentation Materials Available)
  • 2017-05-01 The 6th APAC Meeting: Thank You for the Conference Participants
  • 2017-04-03 The 6th APAC Meeting: Meeting Program and Venue
  • 2017-02-17 The 6th APAC Meeting: General Information
  • 2017-01-26 The 9th Asia Regulatory Conference (ARC): Register Now!
  • 2017-01-18 The 6th APAC meeting on April 5-6, 2017 in Tokyo

WHAT WE BELIEVE

Pharmaceutical conferenceAPAC is an industry-driven initiative led by R D-based pharmaceutical associations from Asian economies, aiming to fulfill its mission.

Our Mission

To expedite the launch of innovative medicines for the peoples in Asia

Our Goals

In order to fulfill its mission, APAC proposes the concept of “Access to Innovative Medicines (ATIM)”, the achievement of which is the ultimate goal of APAC, as illustrated below with a description of the scope of priorities that APAC should address. Ongoing activities in the fields of “Drug Discovery Alliances (DA)” and “Regulations and Approvals (RA)” are the priorities that APAC has been tackling as a first step towards the achievement of ATIM.

APAC will continue to take up other priorities step by step as it contributes to the health of the people in Asia.

Pharmaceutical conference

Pharmaceutical conference





PNP Pharmaceuticals – Contract Manufacturers of Nutraceutical and Pharmaceutical Products, pharmaceutical contract manufacturers.#Pharmaceutical #contract #manufacturers

pharmaceutical contract manufacturers

PNP Pharmaceuticals is a unique contract manufacturer of nutraceutical and pharmaceutical products. We are a highly accredited company with an emphasis on quality and service, on a level which sets us apart from our competitor. From the minute, you enter our facility or speak to us via telephone our commitment to excellence is clearly evident.

We are simply different, from our unrivaled service, knowledge and expertise, and overall quality, to our professional yet friendly demeanor. We are a young, energetic, and exciting company that strives to be the best at what we do; manufacture quality products.

PNP Pharmaceuticals’ commitment to excellence begins with genuine dedication of each and every employee. We diligently perform our specific duties without compromise to ensure all products manufactured are of the finest quality possible.

We at PNP Pharmaceuticals are strong in our convictions to see our commitments are never compromised, for that reason we promise that ethics will always take precedent over profits.

Our newly constructed facility is over 78,000 square feet in size located in Burnaby, British Columbia, Canada. We are 15 minutes from Vancouver International Airport and only 20 minutes from downtown Vancouver.

Our manufacturing facility meets or exceeds all GMP requirements and includes:

  • Negative pressure Hepa filtered air throughout all production rooms to eliminate cross contamination.
  • All plant air is humidity monitored and controlled to eliminate mold and bacteria growth and maintain material stability
  • Production area air is supplied with 100% sterile air via UV light system.
  • All plant air is temperature controlled
  • Production area floors are chemical resistant MMA with coved corners for durability and ease of cleaning.
  • Walls are non-porous fiberglass or custom paint for easy cleaning
  • Refrigeration and freezing units.
  • 24 hour security surveillance, HD internet camera and alarm monitored

Our facility was designed for function as well as employee comfort therefore extra glass was incorporated wherever possible to give the production area a staff friendly feel.

PNP Pharmaceuticals has brought together a talented team of professionals that collectively bring a wealth of knowledge from their specific fields of expertise.

  • Glen North, President CEO

Glen is the co-owner and founder of PNP Pharmaceuticals and has over 25 years experience in the pharmaceutical/nutraceutical industry. Before establishing PNP Pharmaceuticals in 1999, Glen owned and operated a successful chain of retail vitamin stores in British Columbia. Glen’s vision and strong leadership has guided PNP Pharmaceuticals to become one of Canada’s largest and most respected contract manufacturers.

Dennis is the co-owner of PNP Pharmaceuticals. Dennis retired as an MD following a 20 year career as a General Physician. He received his medical training in Hong Kong and post graduate in the UK. Recently he was clinically attached to St. Paul’s hospital in Vancouver, B.C.

Tony joined PNP Pharmaceuticals in October 2012. He became certified as a Chartered Accountant in 2011 and remains an active member of the Institute of Chartered Accountants of BC. Before joining PNP, Tony worked at KPMG LLP as an audit and accounting professional while attending the Chartered Accounting School of Business. Over the years, Tony has overseen the financial reporting and accounting duties in PNP’s manufacturing environment with his professional experience, knowledge and due diligence. He holds a Diploma in Accounting from the University of British Columbia and a Bachelor’s Degree in Economics/Finance from the University of Waterloo.

Warren joined PNP in 2008, bringing with him 20 years of experience in Sales and Marketing garnered in the Forest Products Industry. His vast experience managing large accounts in the international marketplace, combined with his attention to detail and natural proficiency to provide the highest levels of customer service, make him a valuable asset to the team.

Peter’s 11 years experience began in contract OTC Pharmaceutical manufacturing in the UK for customers that included SmithKline Beecham and Whitehall Laboratories. Upon moving to Canada in 1999, he joined Dairyland and gained experience in the Dairy industry. In 2001 he joined Quest Vitamins/Boehringer Ingelheim/PanGeo Pharma/Jamieson Laboratories Ltd, where he held the position of QA Supervisor. He has a Bachelors of Science degree in Microbiology from the University of Kent at Canterbury, England.

Wendy joined PNP in 2008 and is a Certified General Accountant (CGA). Wendy also holds a Bachelor’s Degree of Applied Mathematics from GuangZhou University, Canton, China, as well as a Finance Management Diploma, from Langara College in Vancouver, B.C.

  • Maria Consolacion Manuel, Quality Assurance Manager

    Maria brings over 15 years experience to PNP Pharmaceuticals in the field of pharmaceutical manufacturing, quality assurance/control, cGMPs and regulatory standards. Prior to joining PNP Pharmaceuticals Maria held the title as QA/QC Manager for the largest contract pharmaceutical manufacturer in Asia, serving major international clients such as Bristol-Myers Squibb, Eli Lilly, Boehringer Ingelheim, Schering, Bayer, Otsuka, and Hoffman-La Roche. Maria holds a Bachelor of Science degree in Chemistry and is pursuing academic training in Quality Management at BCIT.

    Robert joined PNP Pharmaceuticals in 2004 and oversees all components of production. Prior to PNP, Robert served as Chairman and General Manager with a company overseas. He holds Masters of Science and Business Management Degrees from the University of Huazhang, China.

  • Alan Urmeneta, Purchasing Logistics Manager

    Alan has over 13 years experience in purchasing, Materials Management and logistics training in a pharmaceutical environment. Alan previously spent 15 years with Jamieson Laboratories Ltd./ PanGeo Pharma Inc./ Boehringer Ingelheim /Quest Vitamins

    Abdul has over 19 years of experience in the pharmaceutical industry. His experience includes all aspects of the industry including Production, QA, QC, Validation, Formulation and Regulatory Affairs. Abdul holds a Bachelor’s Degree in Science and Master Business Administration in addition to a number of training certifications in the pharmaceutical industry including validation.

    Emilie studied Biochemistry in France and joined our team in 2015. Starting her career in the Flavour Industry, she spent 7 years working with Food and Natural Health Products manufacturers acquiring a strong technical expertise in regards to ingredients, formulations and applications. By the diversity of the Food and Natural Health Product Industry, Emilie is bringing her experience to PNP sales team and has been a valuable asset.

    As Human Resources Advisor, Helen leads the HR function at PNP Pharmaceuticals. She works collaboratively with managers on performance management, employee relations, benefits and compensation, and health and safety. Helen has over 7 years of experience as an HR Professional and is a certified member of the Human Resources Management Association. Helen takes pride in creating a culture that is fun, inclusive, and performance drive.

  • Pam Elliott, Director of Product Development

    Pam has worked in the Natural Health and Pharmaceutical industry for over 17 years – in positions encompassing Quality, Regulatory, Formulation, Technical Sales and Customer Relations roles. In 1999, as Health Canada’s Natural Health Directorate was coming into inception, Pam’s Analytical Chemistry focus took her to work at Natural Factors, one of North Americas largest Natural Health Product Manufacturers, as the Quality Control Lab Manager overseeing the Analytical Testing Lab and QC Sampling departments. She went on to work for 11 years at LV Lomas, a leading North American distributor of Pharma, NHP and food specialty ingredients, where she received training from top ingredient manufacturers, assisted customers in developing formulations using both standard and multifunctional ingredients, and aided customers with formulation and production challenges through collaboration with industry technical specialists and hands-on customer plant trials.

    Raveen has over 5 years of sales and account management experience within the Pharmaceutical and Dietary Supplement Industry. Raveen’s goal is to help his customers achieve success. Raveen works closely with various brands to understand their manufacturing requirements so that PNP can deliver with excellence.





  • Compressed Air Systems, Inc, pharmaceutical companies in charlotte nc.#Pharmaceutical #companies #in #charlotte #nc

    800.745.0348

    Pharmaceutical companies in charlotte nc

    Pharmaceutical companies in charlotte ncPharmaceutical companies in charlotte ncPharmaceutical companies in charlotte ncPharmaceutical companies in charlotte ncPharmaceutical companies in charlotte ncPharmaceutical companies in charlotte ncPharmaceutical companies in charlotte ncPharmaceutical companies in charlotte nc

    Pharmaceutical companies in charlotte nc

    Pharmaceutical companies in charlotte nc

    Pharmaceutical companies in charlotte nc

    Pharmaceutical companies in charlotte nc

    Pharmaceutical companies in charlotte nc

    Pharmaceutical companies in charlotte nc

    Our Purpose..

    Pharmaceutical companies in charlotte nc

    Compressed Air Systems has been providing professional equipment sales, system design, installation, 24/7 service for compressed air and industrial vacuum systems to customers in North Carolina, South Carolina and Central Virginia since 1984. Our goal is to provide the best technical support, products and service available in our trading area. Over the last 30 plus years, we have developed a staff of Systems Engineers, Factory Trained Service Technicians, and heavily experienced Parts and Support personnel. Our staff of industry experts makes Compressed Air Systems the best option for your compressed air and vacuum requirements.

    Compressed Air Systems, Inc. is an authorized distributor of Atlas Copco Compressors, a world-leading manufacturer of compressed air solutions, industrial vacuum pumps, and air treatment systems. Compressed Air Systems has partnered with Atlas Copco, and this partnership allows Compressed Air Systems to offer the most innovative, efficient and long lasting equipment solutions to our valuable customer base. With highly trained and factory certified Sales Engineers and Service Technicians located throughout North and South Carolina and Virginia, we are strategically positioned to serveyour compressed air needs. To learn more, visit The Compressed Air Blog.

    Service Maintenance Lubricants Filters 24/7 Repairs Installations System Surveys

    Pharmaceutical companies in charlotte nc





    Pharmaceutical GMP Professional Certification (CPGP), ASQ, pharmaceutical information.#Pharmaceutical #information

    Pharmaceutical GMP Professional Certification CPGP

    Process: Learn Prepare Apply Certify Recertify

    The Certified Pharmaceutical GMP Professional understands the good manufacturing practices (GMP) as regulated and guided by national and international agencies for the pharmaceutical industry. This covers finished human and veterinary drugs and biologics, ectoparasiticides, and dietary supplements (alternatively called nutraceuticals) where regulated as drug products, as well as their component raw materials (includes active pharmaceutical ingredients (APIs) and excipients), and packaging, and labeling operations.

    ASQ Members $348 (save $150)

    Price includes $70 non-refundable fee.

    ASQ Certification Prep Resources

    Requirements

    Here are the minimum expectations, requirements, experience and exam specifics for a Certified Pharmaceutical GMP Professional.

    Work Experience

    Work experience must be in a full time, paid role. Paid intern, co-op or any other course work cannot be applied towards the work experience requirement.

    Candidates must have five years of on-the-job experience in one or more of the areas of the Certified Pharmaceutical GMP Professional Body of Knowledge. A minimum of three years of this experience must be in a decision-making position. Decision-making is defined as the authority to define, execute, or control projects/processes and to be responsible for the outcome. This may or may not include management or supervisory positions.

    Education

    There are no education waivers for this exam.

    Expectations

    Here are the minimum expectations of a Certified Pharmaceutical GMP Professional.

    • Will have a fundamental understanding of regulatory agency governance including, global regulatory framework, relevant regulations and guidelines, and mutual recognition agreements.
    • Will be able to develop and apply elements and requirements of a quality system, evaluate various types of audits and self-inspections, and analyze documents and record management systems.
    • Will be able to distinguish between and verify suitability of factors relating to laboratory systems, including relevant compendia for U.S., Europe and Japan, investigations of aberrant laboratory results, and instrument control and record-keeping.
    • Will be able to determine requirements and specifications for construction of facilities, utilities and equipment, evaluate automated or computerized systems, and apply business continuity plans and disaster recovery techniques.
    • Will be able to use sampling plans and apply procedures for shipping and receiving materials, analyze in-house storage, identification, and rotation of materials, and meet requirements for materials traceability and sourcing, including returned goods.
    • Will have a thorough understanding of sterile and nonsterile manufacturing systems and be able to analyze master and completed batch records, material control procedures, and contamination controls.
    • Will have a thorough understanding of product design factors and phase-appropriate GMP requirements. Will be able to develop and evaluate filling and packaging operations and controls, and analyze technology transfer activities.

    Body of Knowledge

    This BOK includes subtext explanations and corresponding cognitive levels for each topic or subtopic. These details will be used by the Examination Development Committee as guidelines for writing test questions and are designed to help candidates prepare for the exam by identifying specific content that can be tested.

    The subtext is not intended to limit the subject matter or be all-inclusive of what might be covered in an exam but is intended to clarify how topics relate to the role of the Certified Pharmaceutical GMP Professional (CPGP). The descriptor in parentheses at the end of each subtext entry refers to the highest cognitive level at which the topic will be tested. A more complete description of cognitive levels is provided at the end of this document.

    Please Note: The Body of Knowledge for certification is affected by new technologies, policies, and the changing dynamics of manufacturing and service industries. Changed versions of the examination based on the current Body of Knowledge are used at each offering.

    Download the Certified Pharmaceutical GMP Professional Body of Knowledge





    Top 10 PCD Pharma Companies in India – 2017 List by Fossil Remedies, top pharma

    List of Top 10 PCD Pharma Companies in India

    Top pharma companies

    Top 10 PCD Pharma Companies in India

    Fossil Remedies

    Having headquarters in Ahmadabad, Gujarat, ‘Fossil Remedies’ is the top most Pharma franchises company in India with long years of experience.They manufacture and market more than 2800+ Pharma products and indulge in 8 Special divisions . They offer franchise and PCD Pharma distributorships to interested parties.

    Some of their product ranges are:

    400+ Antibiotics and general products

    150+ Cardiac Diabetes Product

    150+ Skin Cosmetic Products

    100+ Gynec Hormones Products

    50+ Ophthalmology Products

    Fitwel Pharma

    Another leading Pharma company in Ahmadabad, Gujarat is ‘Fitwel Pharmaceuticals’. This company is awarded with ISO 9001:2008 for its high quality products ranging nearly 200.‘Fitwel Pharmaceuticals’ strongly follows affordable price, best quality, prompt delivery, innovative products , products availability and prompt settling of queries.

    Frank Medilink

    This Pharma Company in Ahmadabad, started in 2008, introduces itself as integrated franchise PCD Pharma Company.It started marketing to eastern part of India and then expended to other parts of India. This is also an ISO 9001:2008 certified company.

    Cubit Healthcare

    Cubit Healthcare is a integrated franchise (PCD) pharmaceutical company. It is a leading player in the franchise business in the country. It has a significant presence in brands across all therapeutic segment like from cough cold to life threatening serious diseases.

    Progressive Life Care

    As one of the leading Pharma companies in Gujarat that is in the top ten companies list, this company specializes in more than 200 life care products. They offer PCD Pharma franchises opportunities for marketing in its, own state and all through India.

    Ambit PCD Pharma

    Another top PCD Pharma company from Ahmadabad, Ambit PCD Pharma supplies quality prescription products from 2006 onwards. This ISO 9001:2008 company has WHO GMP certified plants through which they produce nearly 250 Pharma products.

    Radico Remedies

    This leading PCD Pharma Company is located in Baddi, Himachal Pradesh of India. With its 30 years of experience, they excel in producing excellent quality Pharma products in dermatology, neuro psychiatry, ophthalmology, veterinary and generics.

    Green Cross Remedies

    With 20 years of experience, this ISO certified PCD Pharma Company offers ethical based PCD Pharma franchise opportunity to dealers, distributors and medical representatives from all over India to get PCD Pharma Franchise with 100% monopoly.

    Tesni Pharma

    This ISO 9001-2008 Certified Company has WHO GMP certified plants through which they produce large amount of Pharma Products. At Tesni Pharma, we offer a highly profitable platform to the Pharma companies as well as to the investors who want to get into the PCD Pharma business.

    Zubit Lifecare

    Started in 2001 in Ahmadabad, Gujarat, this PCD company deals in more than 350 Pharma products.





    PharmTech Home, pharmaceutical contract manufacturers.#Pharmaceutical #contract #manufacturers

    pharmaceutical contract manufacturers

    Pharmaceutical contract manufacturers

    Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseases

    Pharmaceutical contract manufacturers

    Using Human Challenge Trials to Develop Flu Vaccines

    Pharmaceutical contract manufacturers

    Moving to Closed Systems for Aseptic Processing

    Pharmaceutical contract manufacturers

    Cold Chain: Delivering Vaccines to Patients

    Pharmaceutical contract manufacturers

    Accelerating Vaccine Development and Manufacturing

    Pharmaceutical contract manufacturers

    Achieving Intensification and Flexibility in Virus Purification with N.

    Pharmaceutical contract manufacturers

    Operational Best Practices

    Pharmaceutical contract manufacturers

    Your Online Resource to Global Suppliers

    Top News

    EMA to Relocate to New HQ in Amsterdam in Wake of Brexit

    Nov 21, 2017

    Following a vote by member states in favor of Amsterdam as the agency’s new headquarters, the relocation will take place over the next 16 months, with operations expected to start up in March 2019.

    FDA Approves Digital Pill

    Nov 14, 2017

    The agency approved Abilify MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication.

    FDA to Recognize Inspections from EU Drug Authorities

    Oct 31, 2017

    A mutual recognition agreement to accept inspection data from eight EU regulatory authorities may reduce inspection burdens at global drug facilities.

    PharmTech eBook Series

    Vaccines Development and Manufacturing 2017 eBook

    Pharmaceutical contract manufacturers

    Vaccines from childhood and influenza immunizations, to epidemic prevention, to cancer and therapeutic treatments present unique development challenges. In this Vaccine and Manufacturing eBook, the editors explore development and manufacturing options to make vaccines more accessible.

    Industry News

    New Report Stresses Importance of Affordable Drugs

    Nov 30, 2017

    Experts slam drug prices and endorse government price negotiations and curbs on drug advertising.

    Sun Pharmaceutical Recalls Riomet

    Nov 27, 2017

    The company is recalling product because of microbial contamination.

    EMA Releases Guidelines on Advanced Therapies

    Nov 27, 2017

    The new guidelines discuss GMPs and patient protection specific to advanced therapy medicinal products.

    Supplier News

    Binding Site Expands mAb Portfolio

    Binding Site has introduced a number of new monoclonal antibodies targeting infectious diseases, including cytomegalovirus, hepatitis (A, B, C, and D), herpes, human immunodeficiency virus (HIV), rubella, and toxoplasma.

    Biocad Announces New Manufacturing Site in North Africa

    Biocad and Sothema Labs have partnered to release cancer-treating biosimilars into the North African market.

    Fette Compacting and Glatt Partner to Develop Continuous Manufacturing Solutions

    Fette Compacting and Glatt have joined forces to develop integrated solutions for the continuous manufacturing of oral solid-dosage drug forms.

    Bio/Pharma News

    AstraZeneca Establishes Joint Venture in China to Develop Innovator Drugs

    The joint venture will focus on the discovery, development, and commercialization of potential new drugs for the global market as well as speed delivery of new medicines to China.

    Teva Restructures Company and Leadership

    In the wake of generic-drug pricing pressure and declining revenues, Teva has restructured its commercial business and made executive leadership changes.

    FDA Approves Roche’s Hemophilia A Biologic and Expands Indication for Leukemia Drug

    The agency has approved a biologic-based new molecular entity for treating hemophilia A and has expanded the indication for a leukemia drug to now treat a common form of non-Hodgkin lymphoma.

    Standards/Regulations

    Will Pharma Meet the Drug Tracking Deadline?

    Manufacturers and trading partners struggle to meet drug tracking requirements

    FDA’s Policy on Regenerative Medicine Therapies

    Commissioner Scott Gottlieb, MD, outlined a plan to support innovation of regenerative medicines while ensuring public safety.

    Gottlieb Sends Message About REMS and Market Competition

    FDA is exploring ways to keep branded drug companies from using REMS to block the development of generic drugs.

    Drug Development

    Biocad Announces New Manufacturing Site in North Africa

    Biocad and Sothema Labs have partnered to release cancer-treating biosimilars into the North African market.

    AstraZeneca Establishes Joint Venture in China to Develop Innovator Drugs

    The joint venture will focus on the discovery, development, and commercialization of potential new drugs for the global market as well as speed delivery of new medicines to China.

    Small and Specialty Companies Shape Pharma’s Evolving Outsourcing Landscape

    Pharma trends translate into increased need for not only external partners, but those will capabilities that can help advance today’s drug development and manufacturing challenges.

    Best Practices

    Best Weighing Practices in the Pharmaceutical Industry

    Understanding what affects a measurement and implementing appropriate procedures will aid weighing accuracy.

    Maintaining Thermal Fluid Systems

    Preventative maintenance of heat transfer fluid systems is important for reducing downtime in pharmaceutical manufacturing.

    Treating Halogenated Hydrocarbon Emissions from Pharmaceutical Production

    Regenerative thermal oxidation (RTO) has become a common solution to treat volatile organic compounds (VOC) and hazardous air pollutants (HAP) present in the emissions of many pharma production processes. Regenerative thermal oxidation devices used to treat halocarbons should be designed to prevent corrosion. Anguil Environmental Systems explains best practices for addressing potential fail points in the materials of construction when designing process emission handling systems.





    Pharm Exec s Top 50 Companies 2017, Pharmaceutical Executive, top pharma companies.#Top #pharma #companies

    top pharma companies

    Pharm Exec’s latest annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.

    With the exception of a few new bottom-end entrants, and some juggling of positions in the top half, stability remains the name of the game for those biopharmaceutical companies making up this year s list of the industry s top 50 global sales leaders (see tables below). Of course, the relative calm in the rankings meter doesn t mean that stability necessarily begets profitability for all. Amid growing pricing pressures, key patent losses for some, and a slowdown in M A activity since the middle of 2016, several mainstays on the Pharma 50 list experienced only modest revenue gains in the latest full-year figures collected, while others suffered slight declines. Pharm Exec s 17th annual listing again features data provided by biopharma market intelligence firm Evaluate Ltd.

    Experts attribute the consistent entrenchment of familiar names in the top 10 and 20 to the simple adage of how business gets done in this industry mainly big pharma following a model that continues to prioritize amassing products and innovation through internal R D, licensing, or acquisition. Pfizer, for example, which repeated as the industry s prescription sales leader, has maintained its hold by applying the latter two. As have companies such as Shire, which spurred by its completed merger of Baxalta in June 2016, shot up from the 30th spot to No. 22 on this year s revenues list. And on the R D side, Shire s investment increased 45.5% to $1.29 billion.

    Merck Co., despite being ranked fourth in sales, is No. 1 in R D spend, with a 47.6% spike in investment versus the previous year. The company s newest rising seller, the immunotherapy Keytruda, continues to be studied across numerous tumor types, lines of therapy, and combinations. Others that didn t climb the sales ranks but are investing solidly in R D include Lilly (15th in sales, eighth in R D spend) and AstraZeneca (11th in sales, seventh in R D).

    As far as future shifts in sales-figure positioning in the Pharma 50, Jonathan Gardner, EP Vantage News Editor, US, at Evaluate, cites two areas to watch. The first is pricing, to the extent where payers become more assertive in areas where they have been reluctant in the past, such as oncology or orphan diseases, Gardner tells Pharm Exec. On the latter, we ve seen payers be surprisingly skeptical of new drugs Spinraza and Exondys 51, and there is potential for that to expand. The second issue is disease areas that have become crowded with new agents autoimmune disorders such as psoriasis and rheumatoid arthritis that could give payers even more leverage than they ve had in the past on franchises such as Humira and Enbrel.

    Gardner also notes that until the outlook on US pricing legislation, tax reform, and repeal and replace of the Affordable Care Act becomes clearer, a big rush on M A is unlikely. Opportunistic deals will appear, but companies with significant amounts of overseas cash will be reluctant to risk overpaying on taxes to execute major US acquisitions, he says. Pricing and ACA repeal/replace pose similar, if lower-level risks.

    Which leads us to our special Pharma 50 accompanying feature by guest authors at the executive search and talent advisory firm Russell Reynolds Associates. The authors contend that a significant disruptive event looms on the horizon for the industry, brought on by new US legislation on pricing and new definitions of value. The article points out that traditional sourcing routes for biopharma innovation in-licensing, M A, and R D collaboration have been expanded by new models of engagement with external innovators, such as open innovation models and corporate ventures. Managing the diversity and complexity of these innovations, and building a more nuanced communication with the external world, will require all those companies in our Pharma 50 to adopt new leadership approaches and install new types of specialists and C-suite roles to guide the collective industry through the coming disruption and beyond.

    See how the top 50 biopharma revenue generators stack up ahead (click on the tables to enlarge).

    Top pharma companies Top pharma companies Top pharma companies Top pharma companies Top pharma companies





    Pharmacy and Pharmaceutical Information on the Internet, pharmaceutical information.#Pharmaceutical #information

    pharmaceutical information

    Pharmaceutical information

    PharmWeb has Closed.

    If you are interested in acquiring the PharmWeb domain names (pharmweb.net, pharmweb.com and pharmweb.org) then please contact me via my LinkedIn page.

    PharmWeb was launched in 1994 as an online community of pharmacy, pharmaceutical and healthcare-related professionals with over 40,000 self-registered users (probably significantly higher as we stopped monitoring in the 90s). PharmWeb was the first pharmaceutical portal and one of the oldest web sites on the Internet when it closed in August 2016.

    PharmWeb was a fantastic achievement and a great deal of fun, particularly in the pioneering wild west days of the early 1990s when the Internet was in its infancy. In 2000 we were the subject of a Ј20 million buyout!

    PharmWeb was only possible with the support of many colleagues, friends and of course the support of my long suffering partner Felicity. I recall in the early days when many colleagues dismissed the (phenomenon that was the) Internet as a flash in the pan! We were not deterred and predicted the information revolution that has come to pass, and indeed many of the services launched on PharmWeb were pioneering at the time. Much of the early services were the result of the programming skills of the team behind PharmWeb as many of today’s off the shelf packages were just a twinkle in a developer’s eye.

    Whilst there are too many people to thank individually, I would like to particularly acknowledge a few people who were part of the PharmWeb journey:

    John passed away in 2010. John was a friend and drinking partner and introduced me to the Internet in the early 1990s with the launch of Mosaic. Development of PharmWeb would not have been possible without John’s knowledge of Unix, programming skills and enthusiasm. He is missed by all those who knew him.

    Tony was an undergraduate and postgraduate student when I was at the University of Manchester. Tony had a passion for technology and whilst much of the software ran off a Unix box, many of the databases and online forms were delivered from a Mac server and Tony was responsible for much of the development work. I have lost touch with Tony, but if you read this, the Apple PowerMac G4 (450MHz) server (running Mac OS 9.0.4) we set up in November 1999 was still in operation until the site closed in 2016!

    Commercialisation within an academic environment has its moments, Rich helped me to maintain my sanity in some of the more interesting moments.

    Mirror Site Hosts

    Many people reading this may not recall the Internet of the 1990s where connectivity across the continents was often patchy. Colleagues across the globe hosted PharmWeb mirror sites, and it was a pleasure to meet some of them in person during my travels.

    • Gail Higgins at The School of Pharmacy and Pharmaceutical Sciences, Faculty of Science, University of Sydney, Sydney, Australia.
    • Newton Pereira at the Department of Pharmacy, University of S o Paulo, Ribeir o Preto, Brazil.
    • Terry Moorby at Industry Canada, Canada.
    • Laszlo L Tornoci and Janos Glanz at Pro Patiente – Health and Medicine, Budapest, Hungary.
    • Kenji Ishikawa and Michiko Yamamoto at The National Institute of Health Sciences, Tokyo, Japan.
    • Elize van Dijken and Banie Boneschans at the Potchefstroom University for Christian Higher Education, Potchefstroom, South Africa.
    • Charles Rezac at The University of Kansas Medical Center, Kansas City, KS, USA.
    • Steve Saklad at The College of Pharmacy, University of Texas, San Antonio, TX, USA.
    • Iosif Vaisman at The School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.

    You can follow the development of the site on the Wayback Machine.

    I hope you enjoyed using PharmWeb, au revoir!

    Some early publications.

    The Internet: (1) A guide to the information superhighway.

    Pharm. J., 254, 29-31, 1995.

    The Internet: (2) Connecting and searching for information.

    Pharm. J., 254, 58-59, 1995.

    The Internet: A global communication tool.

    Int. Pharm. J., 9, 68-72, 1995.

    Internet no panacea – but it’s getting there.

    Information World Review, 108, 22-23, 1995.

    The Internet – hype or panacea.

    Community Pharmacy, March 1996, 16-17, 1996.

    The Communications Revolution.

    Int. Pharm. J., 10, 129-134, 1996.

    The Internet – dream or virtual reality?

    Community Pharmacy, March 1997, 33-36, 1997.

    PharmWeb – pharmaceutical information on the Internet.

    Health Information Management: What Strategies.

    S. Bakker (ed), Kluwer Academic Publishers, Dordrecht, The Netherlands, 219-223, 1997.

    The Internet and PharmWeb.

    Emerging Themes and Technologies in Pharmacy Education

    P. Bourlioux, A. A. Hincal, S. Senel, A. T. Florence (Eds), Safak Press, Turkey, 97-100, 1997.

    Pharm. J., 260, 26-28, 1998.

    The Internet: A tool for delivering and exchanging information.

    Int. Pharm. J., 10, 129-134, 1998

    PharmWeb – pharmaceutical information on the Internet.

    Pharmaceutical Science and Technology Today, 1, 2-4, 1998

    An Internet primer: What does the pharmacist need to know?

    Int. Pharm. J., 14, 7-10, 2000.

    PharmWeb – Copyright . All rights reserved.

    The final home page.

    Full programs of major pharmacy, pharmaceutical and health-related conferences around the world plus the PharmWeb Conference Calendar.

    The PharmWeb Discussion Forum is a collection of discussion groups and mailing lists specialising in specific aspects of medicine, pharmacy, pharmaceutical sciences and health-related issues. The discussion groups and mailing lists are designed to focus on specific areas and are moderated to ensure that discussions are within the scope of a particular discussion group.

    This is a comprehensive database of world wide pharmacy schools. The schools list is in the form of a searchable database and is regularly updated. The database includes contact names, addresses, telephone and FAX numbers, and Internet addresses where available.

    Links to government and regulatory bodies around the world.

    Find helpful medical advice on medications, conditions and diseases online.

    Your directory to pharmaceutical information on the Internet. Includes companies, pharmacies, hospitals, plus much more. Each site is evaluated by our team of researchers before addition to the directory.

    A directory of pharmaceutical and health-related societies around the world. Also included is a list of International Pharmaceutical Federation (FIP) member organisations (including addresses, telephone and FAX numbers).

    Job vacancies in science and the health professions, updated regularly. If you want to be the first to know about a new vacancy why not join the PharmWeb Appointments Alert?

    A repository of pharmaceutical information for educational and research purposes.

    Links to various science and health-related newsgroups.

    Links to pharmaceutical and health-related courses and teaching information.

    A resource of links to sites specialising in science, drugs and health-related subjects. A starting point for information other than pharmacy.

    An A to Z index of information held on PharmWeb.

    PharmWeb was the first hierarchical information resource on the Internet for pharmaceutical and health-related information. How did it all start?

    This page contains information on pharmaceutical publications related to the Internet and considers the applications of the Internet to pharmacy and new online pharmacy services.

    Links to some of the best sites on the Internet including search engines, news, weather, entertainment, and many other interesting sites.

    Find out about the latest developments on PharmWeb.

    How many people use PharmWeb? Detailed access statistics for the main PharmWeb servers.

    Do you want to add or edit any link on PharmWeb, this tells you how to do it.

    What can PharmWeb do for you? A summary of the services that PharmWeb provides.

    Some of the common problems encountered using web browsers.

    Let us know what you think of PharmWeb. Many developments have been the result of user feedback.

    Who does all the work?

    PharmWeb is here as a result of the support of major pharmaceutical and health-related organisations.

    This page contains information on your PharmWeb contact.





    NAPSRx – The National Association of Pharmaceutical Sales Representatives, pharmaceutical representative jobs.#Pharmaceutical #representative #jobs

    pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Obtain Vocational Training For A Career In Pharmaceutical Sales Through The CNPR Pharmaceutical Sales Entry Level Program

    Pharmaceutical knowledge is the basic building block in securing relationships with physician customers.

    Pharmaceutical representative jobs

    Utilize the FREE Pharmaceutical Sales Career Center

    Post your resume and apply for open positions to expose it

    to pharmaceutical companies.

    Pharmaceutical representative jobs

    Train For A Career in Pharmaceutical Sales. Enroll in the CNPR Entry Level Pharmaceutical Sales Program.

    Aspiring pharmaceutical sales applicants should be familiar with clinical pharmacology, medical terminology, plus rules and regulations for selling pharmaceuticals to healthcare professionals.

    Pharmaceutical representative jobs

    Free 3 month trial for all current Pharmaceutical Sales Reps.

    We would like to introduce you to the NAPSRX pharmaceutical sales rep association which has been servicing and working with industry reps since 2002. We look forward to assisting you so sign up today.

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs

    Pharmaceutical representative jobs





    Pharmaceutical Microbiology, pharmaceutical industry overview.#Pharmaceutical #industry #overview

    Pharmaceutical Microbiology

    Microbiology, pharmaceuticals, healthcare and contamination control news and discussion site. Edited by Dr. Tim Sandle (established 2010)

    Pages

    Pharmaceutical industry overview

    Thursday, 30 November 2017

    Hand surgeons provide update on wild animal bites

    Pharmaceutical industry overview

    Wednesday, 29 November 2017

    Bacteria Have a Sense of Touch

    Pharmaceutical industry overview

    Microbiological Culture Media: A Complete Guide for Pharmaceutical and Healthcare Manufacturers

    Pharmaceutical industry overview

    1. Application of Culture Media in Pharmaceutical and Healthcare Microbiology
    2. History and Development of Microbiological Culture Media
    3. The Science of Culture Media
    4. Common Types of Microbiological Culture Media for Pharmaceutical Microbiology
    5. The Media Kitchen and the Preparation of Microbiological Culture Media
    6. Sterilization of Microbiological Culture Media
    7. Quality Control of Culture Media
    8. Microbial Cultures
    9. The Use of Environmental Isolates in Pharmaceutical Microbiology
    10. The Colony Forming Unit
    11. Microbial Identification and Visual Assessment of Colonies
    12. Qualification of Culture-Based Environmental Monitoring Methods
    13. Incubation Strategies for Environmental Monitoring
    14. Culture Media for Sterility Testing
    15. Culture Media for Media Simulation Trials
    16. Culture Media for Microbial Controls During Pharmaceutical Manufacture
    17. Assessment of Culture Media for Water Testing
    18. Culture Media for Cell Culture Work
    19. Diluents and Neutralizers Required for the Pharmaceutical Microbiology Laboratory
    20. Data Integrity, Computerized Systems and Microbiological Culture Media
    21. Auditing Culture Media Suppliers
    22. Industry Practices Relating Culture Media Use
    23. Growth and Culture Based Rapid Microbiological Methods

    Tuesday, 28 November 2017

    Role of gut microbiome in posttraumatic stress disorder

    Pharmaceutical industry overview

    Monday, 27 November 2017

    Risk Based Approach to Environmental Monitoring (webinar)

    Pharmaceutical industry overview

    Product ID: 504486

    • Understanding what environmental monitoring sets out to show, in relation to environmental control
    • Appreciating the limitations of monitoring
    • Understanding risk assessment tools like FMEA and HACCP and how they can be applied to environmental monitoring
    • Worked examples of how to apply risk based approaches for setting monitoring frequencies
    • Worked examples of how to apply risk based approaches for determining monitoring locations
    • Understanding how risk assessment can assist with out-of-limits investigationsWhy Should you Attend
    • To understand different approaches for environmental monitoring through the adoption of risk based methodologies. These tools can either be applied to the workplace or used to benchmark current practice against. The approaches discussed have been presented to FDA and European medicines inspectors.

    Areas Covered

    • An overview of environmental monitoring and a biocontamination control strategy
    • Discussion of environmental monitoring methods
    • Introduction to risk concepts, hazard identification and risk assessment
    • Introduction to FMEA
    • Introduction to HACCP
    • Application of risk tools to elements of the environmental monitoring program, such as assessing contamination risks, setting monitoring frequencies, assessing monitoring locations
    • How to determine if too little or too much monitoring is being undertaken
    • Microbiologists (QA and QC)
    • QC managers
    • Production managers
    • Quality Assurance personnel
    • Cleanroom engineer




    How will the pharmaceutical industry evolve on drug pricing, PBS NewsHour, pharmaceutical companies in chicago.#Pharmaceutical

    How will the pharmaceutical industry evolve on drug pricing?

    High drug prices are a constant consumer complaint about health care. Judy Woodruff sits down with Stephen Ubl, president and CEO of the Pharmaceutical Research and Manufacturers of America, at the Spotlight Health Conference at the Aspen Institute to discuss the Senate Republican health care bill, the prospects for lowering drug prices and the connection between the opioid crisis and the industry.

    Read the Full Transcript

    As the battle over health care rages in Congress, one constant complaint from consumers is over drug prices.

    Judy Woodruff is in Colorado with our look at that issue — Judy.

    The Pharmaceutical Research and Manufacturers association, or PhRMA, is the nation’s largest group representing drug companies.

    Stephen Ubl is its president and CEO. I sat down with him here at the Aspen Spotlight Health Conference today, and began by asking about the latest Republican plan to overhaul Obamacare.

    Stephen Ubl, President and CEO, PhRMA:

    Well, it’s still a very fluid dynamic, as you know. We haven’t taken a formal position on the bill.

    I think it’s clear there is a direction towards more autonomy for states to shape their insurance markets, as well as shaping their own insurance designs. So, we will be very engaged in this discussion, and the prism with which we will look at it is making sure that patients have access to the breakthrough treatments and cures our industry is developing.

    The other major health care associations, hospitals, doctors and others have been pretty critical.

    Is the pharmaceutical industry alone in a way or almost alone in not being as worried, as critical of what the Republicans are doing?

    Well, I think it’s fair to say that those stakeholders are focused on the same issues that we are, but, again, I think the bill is still making its way through the process, and we will be very engaged as the possess unfolds.

    We heard President Trump during the campaign speak about the high cost of prescription drugs. I guess it wasn’t long after the election he talked about the drug companies getting away with murder.

    We’re now hearing, though, that the administration may not be coming down as hard on the pharmaceutical industry as some thought moving to a different system. Is that your sense of what’s happening, that you’re going to get maybe a better treatment from this administration than some had expected?

    I don’t think I want to speculate on what the administration will do in this area.

    I will say that we had a very productive discussion with the president with some of our leadership earlier in the year, and I think the president’s focused on two things. One is ensuring that we continue to lead the world in developing better treatments and cures and, two, on jobs, ensuring that we have more domestic investment in the United States.

    And I think our industry is really poised to deliver on both those fronts. Our industry spends $70 billion a year in research and development, which is more than any other industry. So, in general, we’re encouraged by the direction we’re heading.

    I think everybody agrees drug prices are out of control in this country. Pfizer announced it’s raising the prices of 100 drugs by 20 percent, including some well-known drugs like I guess Viagra and Lyrica.

    Drug companies have been sued, I know, by some state attorneys general, alleged collusion and rising prices. What is going on? What do you see is the problem here?

    Well, I should start by trying to make sure that we’re on the same fact basis.

    So, if you look at Express Scripts, which is a leading PBM in the industry, pharmacy benefit manager, looking at spending in 2016, drug spending went up 3.5 percent. And net prices are up 2.8 percent.

    So, if you went two or three years, prescription drug spending was actually the lowest growing or slowest growing category in health care. We did go through a spike in 2014 and 2015, I would argue, due to some anomalous factors.

    FDA approved a number of new drugs. Medicaid was expanded. And a new cure for hepatitis C was introduced, which revolutionized the treatment of that disease and will obviate the need for liver transplant, as well as reduce the incidence of liver cancer.

    We’re now on the back-half of that spike, if you will. The python has sort of digested the tennis ball. And even CMS’ own actuaries estimate that drug spending will be between 4 and 6 percent for the next 10 years, which is roughly in line with overall health care spending.

    At the same time, a lot of finger-pointing going on in the health care industry between the drug companies, the pharmacy benefit managers, hospitals, insurers. A lot of those fingers are being pointed, though, still at your industry.

    We think there are — we take these issues very seriously. And we think there are pragmatic, consumer-oriented solutions to address some of the issues that have been raised.

    So, for example, a lot of the media attention in the last year is focused on companies that are really nothing like our member companies. They are companies that are taking old drugs without market competition and raising the price dramatically. And we think there are policy solutions, primarily at the FDA, that would address those situations.

    Similarly, we think, as an industry, the pricing model needs to evolve. We need to move away from paying for volume to paying for the value of care.

    And I was reading that’s what the administration is — among the things the administration is looking at.

    I have also read, though, that the critics look at that and say that, in the end, it may work for some people, but it’s not going to work for everybody who needs prescription drugs.

    Well, again, our sector may be a little bit lagging other health care sectors in this movement towards paying based on value, as opposed to the volume of care, but it’s one of the rare areas in health care policy where everyone agrees.

    Payers want to move in this direction, our members want to move in this direction, providers want to move in this direction. Again, take cancer therapy. We want to be able to offer novel discounts. But there’s a number of public policy barriers that stand in the way of moving in that direction.

    One of the fundamental questions I have heard out there is, why can’t, for example, Veterans Administration folks get drug prices much lower than what ordinary people can get? Why can’t there be — why can’t there be some sort of movement in that direction? Why can’t there be negotiations with Medicare over the price of drugs?

    I think there’s been a little bit of clinical trial on this question.

    If you look at countries that have adopted models like the VA on a broad scale, the U.K., for example, what you find is that patients have less access to novel therapies. And we think that would be a movement in the wrong direction.

    So the VA, keep in mind, is a closed system, a small number, relatively small number of hospitals and consumers. If you take those price controls and expand them to the entire market, you’re going to reduce patient access and we think create distortions that impact the rest of the market.

    So we believe it’s much better to move in the direction of negotiations in the private sector between our members and plans, again, to try to achieve some specific metrics tied to patient outcomes and then be reimbursed on a differential basis based on whether the patient actually achieves those outcomes.

    Finally, opioids. As you know very well, I think something like 33,000 people died from opioid abuse in 2015. They expect the number to go up last year, this year, and so on.

    We know towns are overwhelmed. Critics are saying so much of this lies at the feet of drug companies that are promoting drugs that people get hooked on, and then those same companies minimizing or even trivializing the impact.

    How do you, as someone who sits in such a responsible position, look at this?

    I can assure you that — speaking personally on behalf of the industry, that no one trivializes the crisis that we’re facing in this country around opioids.

    But it is a multifactorial crisis. There’s a lot of stakeholders that need to come together on a solution, prescribing physicians, manufacturers, treatment facilities, state and local governments. And, for our part, we’re committed to engaging with all those stakeholders to find solutions.

    And is there going to be a change, do you think?

    Well, just to give you an example, the industry is in favor of mandatory training for health care professionals to learn more about pain management, to learn more about appropriate prescribing. So we want to be part of the solution to this problem.

    Stephen Ubl, pharmaceutical manufacturers association, thank you very much.





    Pharmaceutical Microbiology, pharmaceutical industry news.#Pharmaceutical #industry #news

    Pharmaceutical Microbiology

    Microbiology, pharmaceuticals, healthcare and contamination control news and discussion site. Edited by Dr. Tim Sandle (established 2010)

    Pages

    Pharmaceutical industry news

    Thursday, 30 November 2017

    Hand surgeons provide update on wild animal bites

    Pharmaceutical industry news

    Wednesday, 29 November 2017

    Bacteria Have a Sense of Touch

    Pharmaceutical industry news

    Microbiological Culture Media: A Complete Guide for Pharmaceutical and Healthcare Manufacturers

    Pharmaceutical industry news

    1. Application of Culture Media in Pharmaceutical and Healthcare Microbiology
    2. History and Development of Microbiological Culture Media
    3. The Science of Culture Media
    4. Common Types of Microbiological Culture Media for Pharmaceutical Microbiology
    5. The Media Kitchen and the Preparation of Microbiological Culture Media
    6. Sterilization of Microbiological Culture Media
    7. Quality Control of Culture Media
    8. Microbial Cultures
    9. The Use of Environmental Isolates in Pharmaceutical Microbiology
    10. The Colony Forming Unit
    11. Microbial Identification and Visual Assessment of Colonies
    12. Qualification of Culture-Based Environmental Monitoring Methods
    13. Incubation Strategies for Environmental Monitoring
    14. Culture Media for Sterility Testing
    15. Culture Media for Media Simulation Trials
    16. Culture Media for Microbial Controls During Pharmaceutical Manufacture
    17. Assessment of Culture Media for Water Testing
    18. Culture Media for Cell Culture Work
    19. Diluents and Neutralizers Required for the Pharmaceutical Microbiology Laboratory
    20. Data Integrity, Computerized Systems and Microbiological Culture Media
    21. Auditing Culture Media Suppliers
    22. Industry Practices Relating Culture Media Use
    23. Growth and Culture Based Rapid Microbiological Methods

    Tuesday, 28 November 2017

    Role of gut microbiome in posttraumatic stress disorder

    Pharmaceutical industry news

    Monday, 27 November 2017

    Risk Based Approach to Environmental Monitoring (webinar)

    Pharmaceutical industry news

    Product ID: 504486

    • Understanding what environmental monitoring sets out to show, in relation to environmental control
    • Appreciating the limitations of monitoring
    • Understanding risk assessment tools like FMEA and HACCP and how they can be applied to environmental monitoring
    • Worked examples of how to apply risk based approaches for setting monitoring frequencies
    • Worked examples of how to apply risk based approaches for determining monitoring locations
    • Understanding how risk assessment can assist with out-of-limits investigationsWhy Should you Attend
    • To understand different approaches for environmental monitoring through the adoption of risk based methodologies. These tools can either be applied to the workplace or used to benchmark current practice against. The approaches discussed have been presented to FDA and European medicines inspectors.

    Areas Covered

    • An overview of environmental monitoring and a biocontamination control strategy
    • Discussion of environmental monitoring methods
    • Introduction to risk concepts, hazard identification and risk assessment
    • Introduction to FMEA
    • Introduction to HACCP
    • Application of risk tools to elements of the environmental monitoring program, such as assessing contamination risks, setting monitoring frequencies, assessing monitoring locations
    • How to determine if too little or too much monitoring is being undertaken
    • Microbiologists (QA and QC)
    • QC managers
    • Production managers
    • Quality Assurance personnel
    • Cleanroom engineer




    Veterinarian in Warrenton, VA, Piedmont Pets Veterinary Care, veterinary pharmaceuticals.#Veterinary #pharmaceuticals

    Welcome to Piedmont Pets Veterinary Care

    Veterinarian in Warrenton, VA

    Piedmont Pets Veterinary Care in Warrenton, VA is committed to providing you and your beloved companion with the utmost care and value. Serving Fauquier County and surrounding communities since 2003, our veterinary practice proudly offers a full range of services for dogs and cats of all ages to help them live their best life.

    Contact Us

    It is our mission to provide affordable, quality veterinary care to cats and dogs with the utmost compassion.

    Pet of the Month

    Veterinary pharmaceuticals

    To keep your companion feeling their best, we provide regular check-ups, laser therapy, digital x-rays, surgical services, flea and tick control, dietary counseling, dentistry and more. We also maintain a complete inventory of pharmaceuticals, and have an in-house laboratory.

    We have a compassionate team that will give your pet the attention they deserve, while our facility is designed to ensure visitors feel welcome and comfortable. At Piedmont Pets, we understand your pet is your best friend, so we will do everything we can to ensure they are happy and healthy.

    For more information about our veterinary services or to schedule an appointment, contact us today at (540) 349-7200. We look forward to meeting you and your companion!

    See what our clients have to say!

    “The staff and vets at Piedmont Pets are very nice and friendly. They are accommodating to whatever I may need. I would highly recommend them!”

    Veterinary pharmaceuticals

    Veterinary pharmaceuticals

    Veterinary pharmaceuticals

    Veterinary pharmaceuticals





    Medzilla; Biotech Jobs, Pharmaceutical Jobs, Pharmaceutical Sales Jobs, Resumes, Medical Career, Job Board, Biopharmaceutical Jobs,

    MedZilla

    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs

    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs
    • Pharmaceutical representative jobs

    This Week’s Featured Jobs

    Opportunity posted by Sunrise Systems Inc

    Opportunity posted by Lexicon Pharmaceuticals

    Opportunity posted by The Medical Affairs Company

    Opportunity posted by Lexicon Pharmaceuticals

    Opportunity posted by Takeda Pharmaceuticals

    Opportunity posted by PDI, Inc

    Opportunity posted by Novartis

    Opportunity posted by Touchpoint Solutions

    Opportunity posted by Lundbeck

    Opportunity posted by inVentiv Health

    View our Newest Jobs by State

    View our Newest Jobs by Profession

    Employers & Recruiters

    Search now, thank us later:

    Search our pre-screened candidates for the talents you need now for FREE!

    – Mark S, Sales Executive

    – James D, Lab Technichian

    – T. Baker, University of Florida

    – K. Dalton, Clinical Director

    – S. Ohlinger, Pharmaceutical Sales Rep

    – Thom B, ETS Systems

    Job Seekers

    Post your resume to become Medzilla Certified and start getting job offers NOW!

    Post your Resume

    Hot Topics on Our Forums

    ICON offers up to 7K per calendar year for tuition reimbursement. Eligibility begins the 1st of the following month after date of hire.

    Just wonder what CRO provide tuition reimbursement or yearly allowance for school. I am not asking about PMP or ACRP fees for exams etc. This would be for some one that wants to get their MBA, law degree etc.

    Looking for advice from those who are in pharma Sales or recruit for pharma sales. I have always been interested in sales and at the same time I was applying to graduate schools for my teaching certificate, I was also applying to pharma. companies . Read More

    Latest Articles

    The MedZilla.com Employment Report: Permanent R ?>

    Pharmaceutical news, Pharma industry, Pharmaceutical manufacturing, pharmaceutical industry news.#Pharmaceutical #industry #news

    pharmaceutical industry news

    Pharmaceutical industry news

    Pfizer preps French site for UK prescription-free Viagra

    Viagra Connect will be available without prescription in the UK following a request from drugmaker Pfizer, which is preparing a manufacturing site in France for the demand.

    Pharmaceutical industry news

    Glass act: Corning set to expand capacity to tap pharma opportunities

    Corning says it is planning to increase manufacturing capacity for its Valor Glass packaging technology to take advantage of a multi-billion dollar industry.

    Pharmaceutical industry news

    Piramal buys GI OTC brand, Shreya wins manufacturing contract

    Shreya Lifesciences will continue manufacturing Digeplex after selling the gastro-intestinal (GI) drug to fellow Indian drugmaker Piramal Enterprises.

    Pharmaceutical industry news

    Korea development: Celltrion prepping to enter US generics market

    Celltrion Pharm has received an FDA facility inspection in Korea ahead of a first venture into the US generics market.

    Pharmaceutical industry news

    Bio-investment boasts do not diminish Brexit uncertainties

    The UK government has outlined its industrial strategy as it prepares to leave the European Union and boasts of investments and collaborations driving the life science sector.

    Promotional Features

    Pharmaceutical industry news





    Pharmaceutical Companies of Johnson & Johnson, Janssen, pharmaceutical companies in canada.#Pharmaceutical #companies #in #canada

    pharmaceutical companies in canada

    We engage in approximately 400 active collaborations — from discovery to late-stage development — with academia, pharmaceutical and biotech peers, and other public- and private-sector partners.

    Partner With Us

    Together, we can solve problems

    and find transformational solutions.

    We believe that partnerships are essential to drive change, innovation and transformation, and we are committed to ensuring the success of our collaborations.

    Pharmaceutical companies in canada

    Betsy Gross

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

    Pharmaceutical companies in canada

    Cliff Enright

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

    Pharmaceutical companies in canada

    Dennis Owen Frohlich

    Green Tree Repaint

    Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

    Pharmaceutical companies in canada

    Dorethey Gorham

    Day Of The Armada

    Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

    Pharmaceutical companies in canada

    Jane Kielt

    A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”

    Pharmaceutical companies in canada

    Jennifer Jacobs Baruch

    Jennifer is a New York–based artist living with type 1 diabetes.

    Pharmaceutical companies in canada

    Melinda

    Melinda’s artwork reflects her journey living with HIV.

    Pharmaceutical companies in canada

    Rhonda Fenwick

    Through her art, Rhonda has explored psoriasis, a chronic skin disorder she has lived with since the age of six.

    Pharmaceutical companies in canada

    Robert Wright

    Artwork from the National Art Exhibitions of the Mentally Ill, Inc. (NAEMI), an organization dedicated to discovering and preserving the art of people with mental illness.

    Pharmaceutical companies in canada

    Pharmaceutical companies in canada

    Betsy Gross

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses.

    Tap here to expand

    Pharmaceutical companies in canada

    Pharmaceutical companies in canada

    Cliff Enright

    Artwork from The Creative Center at University Settlement, a nonprofit organization dedicated to bringing creative arts to people living with and beyond cancer and other chronic illnesses. Learn more about Cliff’s story, “A Colorful Life”.

    Tap here to expand

    Pharmaceutical companies in canada

    Pharmaceutical companies in canada

    Dennis Owen Frohlich

    Green Tree Repaint

    Diagnosed with ulcerative colitis in 2007, Dennis created an educational website to share his story. Today, his academic career focuses on health communication and exploring the internet’s role in promoting health and well-being.

    Tap here to expand

    Pharmaceutical companies in canada

    Pharmaceutical companies in canada

    Dorethey Gorham

    Day Of The Armada

    Dorethey is a joyful, self-taught artist living with arthritis, general anxiety syndrome and diabetes.

    Tap here to expand

    Pharmaceutical companies in canada

    Pharmaceutical companies in canada

    Jane Kielt

    A retired art teacher and world traveler, Jane has had a passion for art since childhood. Through painting watercolors, she finds inspiration and healing throughout her experience living with multiple myeloma. Learn more about Jane by reading her story “The Art of Getting Lost.”





    Medzilla; Biotech Jobs, Pharmaceutical Jobs, Pharmaceutical Sales Jobs, Resumes, Medical Career, Job Board, Biopharmaceutical Jobs,

    MedZilla

    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information

    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information
    • Pharmaceutical information

    This Week’s Featured Jobs

    Opportunity posted by Sunrise Systems Inc

    Opportunity posted by Lexicon Pharmaceuticals

    Opportunity posted by The Medical Affairs Company

    Opportunity posted by Lexicon Pharmaceuticals

    Opportunity posted by Takeda Pharmaceuticals

    Opportunity posted by PDI, Inc

    Opportunity posted by Novartis

    Opportunity posted by Touchpoint Solutions

    Opportunity posted by Lundbeck

    Opportunity posted by inVentiv Health

    View our Newest Jobs by State

    View our Newest Jobs by Profession

    Employers & Recruiters

    Search now, thank us later:

    Search our pre-screened candidates for the talents you need now for FREE!

    – Mark S, Sales Executive

    – James D, Lab Technichian

    – T. Baker, University of Florida

    – K. Dalton, Clinical Director

    – S. Ohlinger, Pharmaceutical Sales Rep

    – Thom B, ETS Systems

    Job Seekers

    Post your resume to become Medzilla Certified and start getting job offers NOW!

    Post your Resume

    Hot Topics on Our Forums

    ICON offers up to 7K per calendar year for tuition reimbursement. Eligibility begins the 1st of the following month after date of hire.

    Just wonder what CRO provide tuition reimbursement or yearly allowance for school. I am not asking about PMP or ACRP fees for exams etc. This would be for some one that wants to get their MBA, law degree etc.

    Looking for advice from those who are in pharma Sales or recruit for pharma sales. I have always been interested in sales and at the same time I was applying to graduate schools for my teaching certificate, I was also applying to pharma. companies . Read More

    Latest Articles

    The MedZilla.com Employment Report: Permanent R ?>

    INTERNALTIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND ALLIED RESEARCH, pharmaceutical sciences.#Pharmaceutical #sciences

    pharmaceutical sciences

    The International Journal of Pharmaceutical Research and Allied Sciences (IJPRAS) is an open access, online quarterly publishing journal, is a peer-reviewed multi-disciplinary pharmaceutical scientific journal serves scientific information, studies, and scientific outcomes of various international pharmaceutical scientific industries, institutes and forums. IJPRAS is international journal for publication of quality research and review article which belongs to pharmaceutical research and allied sciences.

    The Journal particularly aims to foster the dissemination of scientific information by publishing manuscripts related to current Pharmaceutical as well as Allied sciences fields. IJPRAS publishes full research papers presenting original, high quality research, critical review articles providing comprehensive analysis of research development within a defined area.

    IJPRAS is positioned as a leading specialist reference resource of academic information and analysis on pharmaceutical and Allied sciences, highlighting new concepts and theories, and fresh practical ideas and initiatives that can be readily applied in the pharmaceutical and Allied science industries. The journal provides an intellectual platform for discussion and dissemination of new ideas and latest research in pharmaceutical and Allied science.

    The aim of IJPRAS is to publish peer reviewed research and review articles rapidly without delay in the developing field of pharmaceutical research and allied sciences. IJPRAS publishes articles that enrich the practice of pharmaceutical and Allied Sciences marketing while simultaneously making significant contributions to the theoretical advancement of the discipline. All articles appearing in the journal are peer reviewed to ensure academic rigour and practical relevance.

    Applying the research concept in the pharmaceutical and Allied sciences sectors has recently caught the attention of scholars and practitioners alike. However, Research concept practice as applied to these sectors remains relatively under-explored. The purpose of this new journal is to bridge this gap, and to advance our theoretical and empirical understanding of Research in the field of pharmaceutical and allied sciences.

    The IJPRAS publishes research work, studies, scientific outcomes, critical reviews, etc. in the following two main streams of knowledge:

    Pharmaceutical Sciences: Pharmaceutics, Formulation Science (Solids, Topical, Parenteral NDDS), Polymer Sciences, Pharmacology Toxicology, Nanotechnology, Medicinal Chemistry, Biopharmaceutics, Pharmacoeconomics, Pharmacognosy, Pharmacovigilance, Pharmacogenomics, Biotechnology, Pharmacoinformatics, Pharmaceutical Technology, Drug Regulatory Affairs, Pharmaceutical Technology Analytical Chemistry etc.

    Allied Sciences: Biology, Medical Sciences, Psychology, Health Outcomes Research, Evidence Based Medicine, Microbiology, Neurosciences, Pathology, Biomaterial Sciences, Natural Chemistry, Green Chemistry, Physiology, Biochemistry, Agronomy, Animal Veterinary Sciences, Environmental Sciences, Food Food Industry etc.

    Important Links

    Pharmaceutical sciences





    Buy Steroids Online – Steroids for Sale, pharmaceutical steroids.#Pharmaceutical #steroids

    24ROIDS.BIZ

    Steroids for sale at legal steroids pharmacy.

    24roids.biz offers the opportunity to buy steroids online of very high efficiency. No matter whether you re a beginner or a professional bodybuilder, on this web store you will find a wide range of legal anabolic steroids, shipped directly from worldwide leading manufacturers: Kalpa Pharmaceuticals, Dragon Pharma, Balkan Pharmaceuticals, Geneza Pharmaceuticals, British Dragon, Body Research, Gen-Shi Laboratories, Sciroxx.

    Steroids orders are being shipped worldwide, no matter if you live in USA, UK, Ireland, South Africa,France, Germany, Spain, Canada or Australia etc. and the delivery of order is guaranteed because it directly targets our reputation. To exclude any doubts, all steroids online purchases come with a reshipping policy for missing, seized or damaged packages.

    24roids.biz can afford to sell steroids legally at discount competitive bulk prices, because, as mentioned above we are an approved anabolic steroid supplier and not an intermediate or affiliate site or worse scammers. (You can convince yourself by placing a small order). Our main goal is not just the steroids sale, but bodybuilding performance, that can be obtained by using genuine anabolics from this store.

    • High quality original products
    • All information are 100% confidential
    • Worldwide shipping
    • Free shipping on order over $500
    • Discounts for loyal customers
    • Safe payment options
    • Customer support
    • No prior prescription
    • Discreet delivery

    We understand that we are dealing with products of high level risk, thus we take the full responsibility for all anabolic steroidssold on this site and we are glad to assist you at all levels, starting from the online steroids shopping and finishing with the receipt of your order as well as gaining the desired result. Do not hesitate to convince yourself of this and feel free to contact us with any questions 24/365.

    Bodybuilding and Anabolic Steroids Usage

    When it comes to bodybuilding everyone wants to be bigger in short terms, usually this drives to anabolic steroids use. This can be dangerous and could cause permanent side effects. If you want to go ahead and use anabolic steroids anyway please see a doctor and get weekly checkups done to ensure your body is healthy.

    For this reason we supply legit well known pharmaceutical brands that have been around for a long time and trustful for professional bodybuilders. We deal with anabolic steroids for stacks, cycles, human grade hormones, ancillaries for post cycle therapy, fat burners and sexual enhancements supplements. Our pharmaceutical store carries all of the top muscle enhancers and anabolic steroids online, available for safe use.

    Where to Buy Steroids Online Safely?

    If you are looking for a website where to buy anabolic steroids you have come to the right place. 24roids.biz purpose is to offer best steroids online that will help to gain weight and put on impressive muscles extremely fast.

    Our portfolio of businesses, geographies and anabolic products gives an edge in an increasingly competitive global pharmaceutical market and allows providing affordable anabolic steroids for sale to athletes, bodybuilders and sportsmen across the world, regardless of geographic and social-economic barriers. Approximately 80% of the international sales of anabolic products are generated on the North American market (USA, Canada) and West European market (UK, Spain, France, Germany).

    In case you decided to buy steroids online from our store and need more information on how to order anabolic steroids and available discounts, you can contact us by writing a ticket. We guarantee that all steroids for sale on this site are 100% genuine and extremely powerful.

    Legal Steroids Sale Online: Bodybuilding Supplements, Peptides and Pro-hormones

    Please note that we don t sell steroids to people under the age of 21 and it s your responsibility to make sure that steroids aren t illegal in your country. We strongly oppose the anabolic steroids abuse or any illegal or banned substances usage. Our main purpose is to bring you legal steroids to help you achieve your bodybuilding goals. All steroids for sale contain only ingredients that are well established dietary supplements and contain nothing illegal or banned. Currently our pharmacists are working very hard at creating the perfect steroids cycles and blends to provide you with the most powerful legal steroids sale ever.

    *** You must be at least 21 years old to buy steroids online on this anabolic store.

    24roids.biz offers exclusive high quality legal steroids for sale.

    ★ FREE shipping on order over $500 .

    Pharmaceutical steroidsPharmaceutical steroids





    Pharmaceutical Society of Northern Ireland – The regulatory and professional body for pharmacists in Northern

    Publication of the Corporate Strategy for 2017 22

    The Council of the Pharmaceutical Society NI has published its Corporate Strategy 2017-2022. The Corporate Strategy sets out Council’s Vision of being recognised and trusted as a leader for modern and effective healthcare regulation with a key role in ensuring pharmacy services are safe and meet high standards. The Strategy also sets out Council’s Mission, along with six key objectives and related goals for the five year period.

    Code of Ethics Standards

    Raising Concerns

    Governance

    Fitness to Practise

    Search the register

    Latest news and information

    The President of the Pharmaceutical Society NI, Dr Jim Livingstone, today (6/11/17) welcomed the publication by the Department of Health of the initial findings of the Consultation on the Future of Pharmacy Regulation in Northern Ireland.

    In a statement Dr

    The Council of the Pharmaceutical Society NI has launched an eight week consultation on draft Premises Standards, closing at 12 noon on Monday 27 November 2017. In preparation for commencement of new legislation, the Pharmaceutical Society NI is proposing

    The President of the Pharmaceutical Society NI, Dr Jim Livingstone, has welcomed the introduction of new Regulations in relation to the annotation of pharmacists as Independent Prescribers.

    Speaking today Dr Livingstone said, “Since identifying that specific regulations were not in

    The Council of the Pharmaceutical Society NI, approved the Annual Report for the year 2016-17, at its meeting on Thursday 14 September. This Report has been laid, as required, in the Business Office of the Northern Ireland Assembly and

    The following individuals have been removed from the Register of Pharmaceutical Chemists in Northern Ireland for non payment of fees, in accordance with Article 15(3) of the Pharmacy (Northern Ireland) Order 1976.

    Removal is effective from 1 September 2017 (inclusive).

    Pharmaceutical information





    Here – s how drug companies game the patent system – Chicago Tribune, chicago pharmaceutical

    Here’s how drug companies game the patent system

    The Senate Health Committee held a hearing Oct. 17 about why prescription drugs cost so much and what might be done to make them more affordable. According to the committee’s website, the witnesses included a lobbyist for the pharmaceutical industry, a lobbyist for the pharmacy industry and a lobbyist for the pharmacy benefits-management industry.

    Might I make a small suggestion? The Republican chairman, Lamar Alexander of Tennessee, and the ranking Democrat, Patty Murray of Washington, should begin their next hearing with a reading of the decision issued Oct. 16 by Federal Judge William Bryson in the matter of Allergan Inc. v. Teva Pharmaceuticals USA Inc. et al. Rarely will you find so clear an explanation for why consumers can’t get relief from spiraling drug prices.

    Bryson is a veteran appeals court judge; since 1994, he has sat on the U.S. Court of Appeals for the Federal Circuit, the panel that hears patent litigation appeals. From time to time, Bryson has been designated by Chief Justice John Roberts to hear patent cases at the district court level. That’s how he wound up hearing the Allergan case.

    Or perhaps I should call it the Restasis case, since that is what the dispute is about. Restasis, Allergan’s $1.5 billion dry-eye medication, made headlines last month when Allergan pulled a now-infamous patent ploy, transferring its patent rights to New York State’s Saint Regis Mohawk Tribe. The idea was that because the tribe had sovereign immunity, potential generic competitors trying to overturn the drug’s patents at the Patent Trial and Appeal Board would be stymied.

    All the tricks in the bag

    But this bit of tribal trickery was only the most recent effort by Allergan to keep generics off the market. The Restasis patent, granted in 1995, was set to expire in 2014. Under the 1984 law that established the generic drug industry, once the patent on a branded drug expires, generics are supposed to flood into the market and bring the price down by 90 percent or more.

    But for some time now, big pharmaceutical companies have found ways to extend their monopolies on branded drugs by preventing lower-priced generics from entering the market. The primary way they’ve done this is by abusing the patent system. In effect, that is what Bryson called Allergan out on.

    He issued two rulings. In the smaller one, he allowed the Saint Regis Mohawks to join Allergan as a co-plaintiff in the litigation while also making it plain that he found the ploy disgraceful. What Allergan seeks, he wrote, is the right to continue to enjoy the considerable benefits of the U.S. patent system without accepting the limits that Congress has placed on those benefits.

    The bigger ruling was his decision to invalidate the patents Allergan was using to fend off Teva, Mylan and other generic manufacturers — the very patents that Allergan was trying to protect by shifting them to the tribe. In a short conclusion at the end of his highly technical, 135-page decision, Bryson outlined, in plain English, how Allergan tried to scam the patent system.

    There is no doubt, he wrote, that Allergan has invented a useful and successful pharmaceutical product. But, he added, the company had been richly rewarded for its development of the drug, with a patent that had given Allergan a monopoly on Restasis for two decades.

    The key patent was named Ding I after its inventor, Shulin Ding. Although Allergan filed a handful of what’s called continuation applications over the years, in 2009 it conceded that it would probably lose additional efforts to extend the life of the Ding I patent. Its reasoning was that a follow-on patent would probably not be granted because the next refinement of the drug was too obvious to merit patent protection.

    But in 2013, with the expiration of Ding I imminent, Allergan withdrew its concession of obviousness and began a serious effort to obtain further patent protection. It applied for, and received, patents that would continue its monopoly until 2024.

    The judge then described some of the moves Allergan made to justify its add-on patents: for instance, it put forth evidence that the Restasis formulation resulted in efficacy levels up to eight times as great as would be expected based on studies of the formulation of the Ding I patent. In fact, this supposed evidence was bogus: The actual clinical results, the judge wrote, show no significant difference in efficacy.

    Another move Allergan made was to use its new patents to preemptively sue the potential makers of generic versions. Bryson called these moves blocking patents, which they certainly were.

    Because it wasn’t part of the litigation, Bryson didn’t mention another sleazy maneuver Allergan used to maintain its Restasis monopoly: It issued a series of citizen’s petitions to the Food and Drug Administration. Citizen’s petitions were created to give individuals and community organizations a voice at the federal regulatory agency. But pharmaceutical companies have essentially commandeered the practice, using citizen’s petitions to delay approval of a generic drug. As of this summer, Allergan had submitted three such petitions related to Restasis.

    And then some

    And there’s more: According to Shire PLC, Allergan has been cutting deals with insurance companies that effectively prevented Shire from selling a competitive product. (Shire recently sued Allergan.) Allergan, meanwhile, has sued the compounding company Imprimis, claiming that it is in violation of FDA regulations. Needless to say, Imprimis makes a dry-eye medication. And of course there was the effort to shift the Restasis patents to the Saint Regis Mohawk Tribe.

    Restasis is Allergan’s second-biggest moneymaker, after Botox. There appears to be very little it won’t do to hold on to its monopoly. After Bryson’s ruling, the company quickly came out with a statement saying that it remains committed to vigorously defending the intellectual property of our products.

    But if Allergan were to truly abide by the spirit of the law, its hold on this particular bit of intellectual property should have expired three years ago. Yet it feels perfectly justified in asking — nay demanding — at least another seven years, until 2024.

    With billions of dollars at stake, it is probably too much to expect pharmaceutical companies to start abiding by the spirit of the law. So the only way to fix the problem is for congressional committees to radically reshape the law surrounding pharmaceutical patents.

    Joe Nocera is a Bloomberg View columnist.





    Medzilla; Biotech Jobs, Pharmaceutical Jobs, Pharmaceutical Sales Jobs, Resumes, Medical Career, Job Board, Biopharmaceutical Jobs,

    MedZilla

    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies

    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies
    • Chicago pharmaceutical companies

    This Week’s Featured Jobs

    Opportunity posted by Sunrise Systems Inc

    Opportunity posted by Lexicon Pharmaceuticals

    Opportunity posted by The Medical Affairs Company

    Opportunity posted by Lexicon Pharmaceuticals

    Opportunity posted by Takeda Pharmaceuticals

    Opportunity posted by PDI, Inc

    Opportunity posted by Novartis

    Opportunity posted by Touchpoint Solutions

    Opportunity posted by Lundbeck

    Opportunity posted by inVentiv Health

    View our Newest Jobs by State

    View our Newest Jobs by Profession

    Employers & Recruiters

    Search now, thank us later:

    Search our pre-screened candidates for the talents you need now for FREE!

    – Mark S, Sales Executive

    – James D, Lab Technichian

    – T. Baker, University of Florida

    – K. Dalton, Clinical Director

    – S. Ohlinger, Pharmaceutical Sales Rep

    – Thom B, ETS Systems

    Job Seekers

    Post your resume to become Medzilla Certified and start getting job offers NOW!

    Post your Resume

    Hot Topics on Our Forums

    ICON offers up to 7K per calendar year for tuition reimbursement. Eligibility begins the 1st of the following month after date of hire.

    Just wonder what CRO provide tuition reimbursement or yearly allowance for school. I am not asking about PMP or ACRP fees for exams etc. This would be for some one that wants to get their MBA, law degree etc.

    Looking for advice from those who are in pharma Sales or recruit for pharma sales. I have always been interested in sales and at the same time I was applying to graduate schools for my teaching certificate, I was also applying to pharma. companies . Read More

    Latest Articles

    The MedZilla.com Employment Report: Permanent R ?>

    How will the pharmaceutical industry evolve on drug pricing, PBS NewsHour, chicago pharmaceutical companies.#Chicago #pharmaceutical

    How will the pharmaceutical industry evolve on drug pricing?

    High drug prices are a constant consumer complaint about health care. Judy Woodruff sits down with Stephen Ubl, president and CEO of the Pharmaceutical Research and Manufacturers of America, at the Spotlight Health Conference at the Aspen Institute to discuss the Senate Republican health care bill, the prospects for lowering drug prices and the connection between the opioid crisis and the industry.

    Read the Full Transcript

    As the battle over health care rages in Congress, one constant complaint from consumers is over drug prices.

    Judy Woodruff is in Colorado with our look at that issue — Judy.

    The Pharmaceutical Research and Manufacturers association, or PhRMA, is the nation’s largest group representing drug companies.

    Stephen Ubl is its president and CEO. I sat down with him here at the Aspen Spotlight Health Conference today, and began by asking about the latest Republican plan to overhaul Obamacare.

    Stephen Ubl, President and CEO, PhRMA:

    Well, it’s still a very fluid dynamic, as you know. We haven’t taken a formal position on the bill.

    I think it’s clear there is a direction towards more autonomy for states to shape their insurance markets, as well as shaping their own insurance designs. So, we will be very engaged in this discussion, and the prism with which we will look at it is making sure that patients have access to the breakthrough treatments and cures our industry is developing.

    The other major health care associations, hospitals, doctors and others have been pretty critical.

    Is the pharmaceutical industry alone in a way or almost alone in not being as worried, as critical of what the Republicans are doing?

    Well, I think it’s fair to say that those stakeholders are focused on the same issues that we are, but, again, I think the bill is still making its way through the process, and we will be very engaged as the possess unfolds.

    We heard President Trump during the campaign speak about the high cost of prescription drugs. I guess it wasn’t long after the election he talked about the drug companies getting away with murder.

    We’re now hearing, though, that the administration may not be coming down as hard on the pharmaceutical industry as some thought moving to a different system. Is that your sense of what’s happening, that you’re going to get maybe a better treatment from this administration than some had expected?

    I don’t think I want to speculate on what the administration will do in this area.

    I will say that we had a very productive discussion with the president with some of our leadership earlier in the year, and I think the president’s focused on two things. One is ensuring that we continue to lead the world in developing better treatments and cures and, two, on jobs, ensuring that we have more domestic investment in the United States.

    And I think our industry is really poised to deliver on both those fronts. Our industry spends $70 billion a year in research and development, which is more than any other industry. So, in general, we’re encouraged by the direction we’re heading.

    I think everybody agrees drug prices are out of control in this country. Pfizer announced it’s raising the prices of 100 drugs by 20 percent, including some well-known drugs like I guess Viagra and Lyrica.

    Drug companies have been sued, I know, by some state attorneys general, alleged collusion and rising prices. What is going on? What do you see is the problem here?

    Well, I should start by trying to make sure that we’re on the same fact basis.

    So, if you look at Express Scripts, which is a leading PBM in the industry, pharmacy benefit manager, looking at spending in 2016, drug spending went up 3.5 percent. And net prices are up 2.8 percent.

    So, if you went two or three years, prescription drug spending was actually the lowest growing or slowest growing category in health care. We did go through a spike in 2014 and 2015, I would argue, due to some anomalous factors.

    FDA approved a number of new drugs. Medicaid was expanded. And a new cure for hepatitis C was introduced, which revolutionized the treatment of that disease and will obviate the need for liver transplant, as well as reduce the incidence of liver cancer.

    We’re now on the back-half of that spike, if you will. The python has sort of digested the tennis ball. And even CMS’ own actuaries estimate that drug spending will be between 4 and 6 percent for the next 10 years, which is roughly in line with overall health care spending.

    At the same time, a lot of finger-pointing going on in the health care industry between the drug companies, the pharmacy benefit managers, hospitals, insurers. A lot of those fingers are being pointed, though, still at your industry.

    We think there are — we take these issues very seriously. And we think there are pragmatic, consumer-oriented solutions to address some of the issues that have been raised.

    So, for example, a lot of the media attention in the last year is focused on companies that are really nothing like our member companies. They are companies that are taking old drugs without market competition and raising the price dramatically. And we think there are policy solutions, primarily at the FDA, that would address those situations.

    Similarly, we think, as an industry, the pricing model needs to evolve. We need to move away from paying for volume to paying for the value of care.

    And I was reading that’s what the administration is — among the things the administration is looking at.

    I have also read, though, that the critics look at that and say that, in the end, it may work for some people, but it’s not going to work for everybody who needs prescription drugs.

    Well, again, our sector may be a little bit lagging other health care sectors in this movement towards paying based on value, as opposed to the volume of care, but it’s one of the rare areas in health care policy where everyone agrees.

    Payers want to move in this direction, our members want to move in this direction, providers want to move in this direction. Again, take cancer therapy. We want to be able to offer novel discounts. But there’s a number of public policy barriers that stand in the way of moving in that direction.

    One of the fundamental questions I have heard out there is, why can’t, for example, Veterans Administration folks get drug prices much lower than what ordinary people can get? Why can’t there be — why can’t there be some sort of movement in that direction? Why can’t there be negotiations with Medicare over the price of drugs?

    I think there’s been a little bit of clinical trial on this question.

    If you look at countries that have adopted models like the VA on a broad scale, the U.K., for example, what you find is that patients have less access to novel therapies. And we think that would be a movement in the wrong direction.

    So the VA, keep in mind, is a closed system, a small number, relatively small number of hospitals and consumers. If you take those price controls and expand them to the entire market, you’re going to reduce patient access and we think create distortions that impact the rest of the market.

    So we believe it’s much better to move in the direction of negotiations in the private sector between our members and plans, again, to try to achieve some specific metrics tied to patient outcomes and then be reimbursed on a differential basis based on whether the patient actually achieves those outcomes.

    Finally, opioids. As you know very well, I think something like 33,000 people died from opioid abuse in 2015. They expect the number to go up last year, this year, and so on.

    We know towns are overwhelmed. Critics are saying so much of this lies at the feet of drug companies that are promoting drugs that people get hooked on, and then those same companies minimizing or even trivializing the impact.

    How do you, as someone who sits in such a responsible position, look at this?

    I can assure you that — speaking personally on behalf of the industry, that no one trivializes the crisis that we’re facing in this country around opioids.

    But it is a multifactorial crisis. There’s a lot of stakeholders that need to come together on a solution, prescribing physicians, manufacturers, treatment facilities, state and local governments. And, for our part, we’re committed to engaging with all those stakeholders to find solutions.

    And is there going to be a change, do you think?

    Well, just to give you an example, the industry is in favor of mandatory training for health care professionals to learn more about pain management, to learn more about appropriate prescribing. So we want to be part of the solution to this problem.

    Stephen Ubl, pharmaceutical manufacturers association, thank you very much.





    University of Veterinary and Pharmaceutical Sciences Brno, pharmaceutical sciences.#Pharmaceutical #sciences

    UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES BRNO

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    Pharmaceutical sciences

    University of Veterinary and Pharmaceutical Sciences Brno

    • a public university with more than 90 years of tradition
    • interesting and promising study programmes in the areas of Veterinary Medicine, Veterinary Hygiene and Ecology, and Pharmacy, taught in Czech and English
    • concentrated in a university campus near the centre of the city
    • the best of traditions combined with modern teaching methods and excellent equipment

    Palackeho tr. 1946/1, 612 42 Brno, Czech republic

    The University of Veterinary and Pharmaceutical Sciences Brno was founded in 1918. At the moment the university consists of three faculties – Faculty of Veterinary Medicine, Faculty of Veterinary Hygiene and Ecology, and Faculty of Pharmacy. The VFU Brno is the only university in the Czech Republic specializing in veterinary medicine, veterinary hygiene and ecology, and just one of two teaching pharmaceutical science. It is found within the City of Brno in the city district of Brno – Královo Pole, in the university campus, where all educational and research facilities are located.





    Pharmaceutical steroids, pharmaceutical steroids.#Pharmaceutical #steroids

    Definitive publications

    The unrivalled breadth of our collection spans research, regulatory information and evidence-based clinical knowledge. MedicinesComplete supports your decision making, whether you work in healthcare, academia or industry.

    Tailored packages

    MedicinesComplete offers tailored packages to suit your exact needs, whether you are an individual or looking for a subscription for your entire organisation.

    Contact us to discuss tailored packages for your organisation.

    Find out about MedicinesComplete for:

    Pharmacies

  • Hospitals and

    Community Care

  • Pharmaceutical

    Community Pharmacies Why use MedicinesComplete?

    MedicinesComplete delivers expert knowledge on drugs and medicines, helping pharmacists make the best clinical decisions for patient care.

    Supporting excellent patient service

    • MedicinesComplete quickly supplies the answers you need, leaving you more time for quality conversations with your patient
    • Medicines optimisation – review the latest research and advice all in one platform
    • Instant and relevant answers to any queries that arise when dispensing prescriptions
    • Trusted and world-leading resources to support Continuing Professional Development
    • Whether you need to refresh your knowledge on a long-standing condition or learn about a new drug, MedicinesComplete has the answers you need

    A trusted companion for the whole pharmacy team

    • Rapidly search over 600,000 pages of evidence-based drug information for help with your daily enquiries
    • Feel confident in your advice to patients as the drug information is regularly reviewed and updated
    • Monthly BNF and BNFC updates provide access to the very latest gold standard drug information, exclusively available through MedicinesComplete
    • Answer your international queries by searching the international drugs and brand names in Martindale

    – Emma Baggaley, Senior Pharmacist, City Health Care Partnership CIC.

    Hospitals and Community Care Why use MedicinesComplete?

    MedicinesComplete delivers expert knowledge for healthcare professionals to prescribe and administer medicines safely, promoting best practice in patient care.

    Ensure correct medicines use and enhance patient safety

    • Instant access to the latest information on prescribing, dispensing and administering medicines safely
    • Summaries and in-depth information on interactions, contra-indications, side-effects and dosage, easily accessible through search
    • Facilitate correct medicines use for all patients with access to information on international safety concerns and guidance on global drugs
    • Minimise medication errors by referring to our extensive information on duplicate therapy, adverse drug reactions and interactions

    Make informed, accountable decisions fast

    • Quickly search a wide range of resources and seamlessly link between results, making sure your decision is fully informed
    • Relax in the knowledge that trusted references such as BNF, Martindale and Stockley’s provide the best and most reliable information available

    A cost effective solution

    • Our specifically designed pricing models provide a cost effective solution to your information requirements

    – Emma Baggaley, Senior Pharmacist, City Health Care Partnership CIC.





  • Content Delivery Platform, Learning Platform, Content Delivery, pharmaceutical delivery.#Pharmaceutical #delivery

    Content Delivery Platform

    The modern cloud-based content delivery platform that provides an unparalleled learning experience. Skillport quickly delivers highly targeted learning—when and where people want to learn. Skillport technology, in conjunction with Skillsoft’s unique combination of content, service and experience builds talent and delivers powerful business outcomes. Skillport offers a full learning experience as a stand-alone learning platform, or it can be easily integrated with your existing business and IT systems.

    Pharmaceutical delivery

    A variety of learning modalities to match individual learning styles.

    Pharmaceutical delivery

    Rich user experience with a beautiful, clean UX design.

    Pharmaceutical delivery

    Analytics, reporting, measurement.

    Pharmaceutical delivery

    Extensive search and discovery.

    Pharmaceutical delivery

    Offers a variety of learning modalities to match individual learning styles.

    Pharmaceutical delivery

    Social and collaborative learning to connect learners across your organization.

    Pharmaceutical delivery

    Mobile access through Skillsoft Learning App.

    Pharmaceutical delivery

    Delivers a full complement of learning options and administration features.

    Skillsoft Learning App

    With 62% of all digital media consumed being consumed on a mobile device 1 , it’s not surpising that Skillsoft developed a dedicated Learning App for our customers. The app puts personalized learning in the palm of learners’ hands anytime, anywhere with Skillsoft targeted videos, courses, books, and audio from world-class thought leaders.

    Pharmaceutical delivery Pharmaceutical delivery

    Android, Google Play and the Google Play logo are trademarks of Google Inc.

    Key Benefits

    Pharmaceutical delivery

    Access Anywhere

    Expanded device support allows employees to access learning content on on iOS and Android smartphones and tablets.

    Pharmaceutical delivery

    On-Device Alerts

    Employees are instantly notified about fresh and featured topics.

    Pharmaceutical delivery

    Easier Access

    Learners can now tag Skillsoft topics and content to access their eLearning topics with the touch of a button.

    Pharmaceutical delivery

    Actionable Insights

    New reporting tools help organizations understand when employees are accessing learning opportunities.

    Alternative LMS Providers

    Our platform support extends to leading learning management system providers. Skillsoft supports both the AICC and SCORM eLearning standards and have clients accessing our learning assets from more than 100 different LMS platforms.

    Read a Brochure

    Skillsoft’s Learning App places timely access to key business resources in the palm of learner’s hands.

    Take a Tour

    Highlights of the searchable, intuitive, social, fast, and mobile-enabled Skillport 8i content delivery system

    Sample a Course

    Get a glimpse inside the new Skillport content experience with this demo of our Engaging Top Performers course

    Download a Whitepaper

    Learning in the Cloud: 10 Factors to Consider





    International Journal of Pharmaceutical Sciences and Research (IJPSR), pharmaceutical sciences.#Pharmaceutical #sciences

    Review Articles

    Antimicrobial resistance has been called one of the world’s most pressing public health problems. Addressing the issue of antimicrobial resistance is one of the most urgent priorities in the fields of public health today. Alarmingly, the development of resistance such as multi-drug resistance towards a number of antibiotics poses a challenge to the scientific community in the discovery of new ther.

    A. Shaista* and P. Amrita

    Department of Pharmaceutical Chemistry, Delhi Pharmaceutical Science and Research University, New Delhi, India.

    A COMPREHENSIVE REVIEW ON HERBAL COSMETICS

    India is a focus for development of Ayurveda, Unani, Siddha, Homoeopathy and another natural herbs based health science (AYUSH). Ayush Pharmaceutical industry having great possible and contingency for saundarya prasadka category (herbal cosmetic) development in future. Natural beauty is blessing and cosmetics help in presenting and increaning the beauty and personality aspects of human beings. Sau.

    R. K. Bijauliya*, S. Alok, M. Kumar, D. K. Chanchal and S. Yadav

    Department of Pharmacognosy, Bundelkhand University, Jhansi, Uttar Pradesh, India.

    BIOMEDICAL APPLICATIONS OF CERAMIC NANOMATERIALS: A REVIEW

    A variety of Nano-biomaterials are synthesised, characterised and tested to find out their potentialities by global scientific communities, during the last three decades. Among those, nanostructured ceramics, cements and coatings are being considered for major use in orthopaedic, dental and other medical applications. The development of novel biocompatible ceramic materials with improved biomedica.

    S. Balasubramanian*, B. Gurumurthy and A. Balasubramanian

    Department of Pharmacology, JSS College of Pharmacy, Udhagamandalam, Tamil Nadu, India.

    ALZHEIMER’S DISEASE: A CHALLENGE INITS MANAGEMENT WITH CERTAIN MEDICINAL PLANTS A REVIEW

    It is well known that some plants have medicinal properties and their knowledge has been accumulated in the course of many centuries, based on different medicinal systems such as Ayurveda, Unani and Siddha. In India, it is reported that traditional healers use nearly 2,500 plant species and 100 plant species serve as regular sources of medicine for the treatment of various diseases. Alzheimer’s .

    G. K. Pratap, S. Ashwini and M. Shantaram*

    Department of Studies in Biochemistry, Mangalore University, Chikka Aluvara, Karnataka, India.

    ROLE OF CHITOSAN AND EUDRAGIT IN POLYMER BASED EXTENDED RELEASE MATRIX TABLETS A REVIEW

    The present article describes the recent role of polymers as carriers for delivery of drug at target site to extending its release. These polymers are widely used in delivery due to their inherent characteristics such as biocompatibility, biodegradability. Chitosan and Eudragit are choice of drug in extended release matrix tablets. Chitosan is an amino polysaccharide polymer which is biodegradable.

    A. Prusty* and B. K. Gupta

    Department of Pharmaceutics, College of Pharmaceutical Sciences, Puri, Odisha, India.

    Research Articles

    SEMI-BATCH AND CONTINUOUS CARBOCHLORINATION OF ZIRCONIA IN A PILOT PLANT FLUIDIZED BED REACTOR: OPTIMIZATION OF OPERATING CONDITIONS VIA RESPONSE SURFACE METHODOLOGY

    Zirconium tetrachloride was produced in a pilot plant fluidized bed reactor via the carbochlorination reaction of zirconia. Minitab software 17 was used for the design of experiment with response surface methodology (RSM) for both semi batch and continuous processes. The operating temperature (800-1200 °C), reaction time (30-90 min) and mean particle size (MPS) (70-130µm) were chosen as the rang.

    M. R. Ghasemi and S. M. Ghoreishi*

    Department of Chemical Engineering, Isfahan University of Technology, Isfahan, Iran.

    EFFECTS OF SURFACTANT TYPE ON RETENTION OF BIOACTIVE COMPOUNDS OF SYZYGIUM AROMATICUM IN SPRAY DRIED LIPID BASED SYSTEMS

    This work investigates the effects of the surfactant system used and of spray drying temperature in physicochemical properties and retention of bioactive compounds of lipid based systems loaded with bioactive compounds of Syzygium aromaticum. Seven formulations were prepared, containing Compritol 888 ato and buriti oil as lipids and maltodextrin DE10 as wall material. The surfactants Poloxamer 188.

    D. F. Cortés-Rojas, C. R. F. Souza and W. P. Oliveira*

    Laboratory of R D on Pharmaceutical Processes LAPROFAR”, School of Pharmaceutical Sciences of Ribeirão Preto, Brazil.

    DIETARY HYPERCHOLESTEROLEMIA INDUCES OXIDATIVE STRESS CHALLENGING SPERMATOGENESIS IN RAT MODEL: A LINK TO POSSIBLE INFERTILITY

    Background: Hypercholesterolemia is rapidly becoming a worldwide epidemic that affects children and adults. Some attempt had made to generalize a relationship between hypercholesterolemia and infertility, but until now it remains scanty. Thus, the aim of the present study was initiated. Methods: Male Wistar rats were divided into four groups of six each (n=6). The first group was control and secon.

    A. Biswas*, U. J. A. D’souza and S. Bhat

    Department of Physiology, Faculty of Medicine, Mahsa University, Kuala Lumpur, Malaysia.

    IMPORTANCE OF CALIBRATION IN FLOW CYTOMETRY ANALYSIS FOR HUMAN ADIPOSE TISSUE DERIVED STEM CELL CHARACTERIZATION

    Human adipose tissue-derived stem cells (hADSCs) are promising for cellular therapy as they are multipotent, which consistently express high CD90, CD105, CD73 and low hematopoietic surface markers. Flow cytometry is a routine technology that is used in most laboratories and can be used to study hADSC characterization, but the instrument needs strict calibration to assure the quality of the results.

    P. Sari, E. Luviah, R. Y. Purwoko and J. A. Pawitan*

    Department of Histology, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

    MOLECULAR MODELLING AND MOLECULAR DYNAMICS STUDIES OF SPECT PROTEIN OF PLASMODIUM FALCIPARUM AND IN SILICO SCREENING OF LEAD COMPOUNDS

    Malaria has been a major life threatening mosquito borne disease. Unavailability of any effective vaccine and recent emergence of multi drug resistant strains of malarial pathogen Plasmodium falciparum continues to cause persistent deaths in the tropical and sub-tropical region. As a result, there is a growing demand for new targets for more effective anti-malarial drugs. A novel microneme prot.

    S. Srivastava, S. Santoshi, B. K. Malik and P. Mathur*

    Centre for Computational Biology and Bioinformatics, Amity Institute of Biotechnology, Amity University Noida, Uttar Pradesh, India.





    School of Pharmacy and Pharmaceutical Sciences – School of Pharmacy and Pharmaceutical Sciences – University

    pharmaceutical sciences

    Pharmaceutical sciences

    Significant strengths in protein therapeutics, genomics and systems pharmacology allow us to maintain top 20 ranking by the American Association of Colleges of Pharmacy for research funding.

    We are ranked #1 in New York State and #22 in the United States by U.S. News World Report, and the premier flagship school of pharmacy in the State University of New York system.

    Specialized programs, wide-ranging national and international experiential education rotations, and interprofessional training give you a highly competititve academic foundation.

    Industry-leading employers recognize our commitment to academic excellence our graduates boast diverse leadership roles in all practice areas of pharmacy and pharmaceutical sciences.

    Our highly trained faculty rank among the very best in their fields, recognized nationally and internationally as outstanding teachers, world-class scholars and groundbreaking researchers.

    Latest News

    Academic Program Highlights

    We provide continuing pharmacy education programs designed to maintain competence and bridge identified gaps in knowledge and skills for pharmacists in all practice settings.

    QUICK LINKS

    Upcoming Events

    Resources for

    Academic Programs

    Departments and Offices

    Research Centers

    Contact Us

    Visit Us

    Find People

    News and Events

    ACPE Accredited

    The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education, the national organization accrediting professional degree programs in pharmacy and pharmacy continuing education providers.

    Pharmaceutical sciences





    Home Page, PhRMA, pharmaceutical companies.#Pharmaceutical #companies

    pharmaceutical companies

    PhRMA represents the country’s leading biopharmaceutical research companies and supports the search for new treatments and cures.

    Advocacy

    From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.

    Science

    Today, cutting-edge medical science is transforming patients’ lives. Discover how scientists and researchers are advancing science.

    Patients

    Patient support and assistance is the top priority for PhRMA’s member companies, who are working hard to improve patients’ lives through the discovery and development of new medicines and treatments.

    Resources

    Explore the Resource Library, the interactive State Map and the Chart Pack reports.

    Search the PhRMA Network

    Stay Connected

    Sign Up for Updates

    Pharmaceutical companies

    Welcome to the future of medicine. Where together, we go boldly.

    Pharmaceutical companies

    PPA strives to improve patient health, advance medical innovation and fuel economic growth.

    Pharmaceutical companies

    The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

    Pharmaceutical companies

    Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

    Pharmaceutical companies

    Learn more about America’s biopharmaceutical companies and how they seek to improve patients’ lives.

    Pharmaceutical companies

    We Work For Health aims to increase awareness by uniting workers throughout the industry.

    Pharmaceutical companies

    Patent protection should always be considered by an inventor during the initial stages of their invention.

    Pharmaceutical companies

    Working to spread awareness and education about the importance of secure drug disposal.





    School of Pharmacy (NDSU), pharmaceutical sciences.#Pharmaceutical #sciences

    Pharmaceutical sciences

    School of Pharmacy

    Pharmaceutical sciences

    The School of Pharmacy, within the College of Health Professions, consists of two departments: Pharmaceutical Sciences and Pharmacy Practice.

    The professional pharmacy program is a joint effort of the Department of Pharmacy Practice and the Department of Pharmaceutical Sciences. Pharmacists work in concert with the patient and other health care providers to promote health and prevent diseases. This is achieved by assessing, monitoring, initiating and modifying patients’ medication therapy to achieve optimal therapeutic outcomes.

    The Pharmaceutical Sciences department focuses on graduate education with the offering of both a MS and a Ph.D. degree programs. The School of Pharmacy also has the option of a few dual-degree programs such as Pharm.D./Ph.D., Pharm.D./MPH and Pharm.D./MBA.

    Our outstanding faculty members are committed to delivery of excellent education, training and actively participating in interdisciplinary research and interprofessional practice experiences. The School’s mission is to support, educate, and train undergraduate, professional and graduate students to become highly skilled and caring healthcare professionals and create new knowledge through excellence in the practice of pharmacy and pharmaceutical research.

    School of pharmacy NEWS

    Cancer doesn’t discriminate. Learn how pharmaceutical sciences faculty such as Dr. Sanku Mallik and researchers across NDSU are targeting cancer to make a difference in diagnosis and treatment.

    Pharmaceutical sciences Pharmaceutical sciences

    Pharmaceutical sciences

    Give a gift every year.

    Make a difference every day.

    Pharmaceutical sciences

    Hours

    Hours are 8:00 a.m. to 5:00 p.m.

    Summer Holiday Break Hours

    Hours are 7:30 a.m. to 4:00 p.m.

    • School of Pharmacy
      • School Information
      • Sudro Building Project
      • Residency Programs
      • Employment

      North Dakota State University

      Mailing address: NDSU Dept. 2650 / PO Box 6050 / Fargo, ND 58108-6050

      Pharmaceutical sciences





    Pharmacy and science news from the Pharmaceutical Journal Publications, pharmaceutical news daily.#Pharmaceutical #news #daily

    pharmaceutical news daily

    21 NOV 2017 17:43

    Hepatitis C and the potential for care delivery in community pharmacy

    14 NOV 2017 15:31

    Bronchiectasis: diagnosis, treatment and management

    7 NOV 2017 15:54

    Communicating with parents and involving children in medicines optimisation

    24 OCT 2017 15:50

    How to diagnose and manage Trichomonas vaginalis

    17 OCT 2017 14:24

    Pharmacogenomics: an overview

    11 OCT 2017 12:02

    Advanced Pharmacy Framework and Foundation programme

    We have mapped many of our learning resources to the RPS Faculty’s Advanced Practice Framework and Foundation programme. To find relevant articles please visit here to pick a cluster.

    Latest

    The implications of the Montgomery judgment on pharmacy practice and patients with learning disability

    28 NOV 2017 15:03

    Pharmacological treatment options for fibromyalgia

    7 NOV 2017 10:26

    Pharmacologic treatment options for children and adolescents with autism spectrum disorder

    10 OCT 2017 15:43

    Antimicrobial therapies for Gram-positive infections

    12 SEP 2017 15:28

    An update on the management of chronic hepatitis B and C infection

    9 AUG 2017 14:46

    Safe dispensing in community pharmacies: applying the software, hardware, environment and liveware (SHELL) model

    Supporting the supporter

    27 NOV 2017 15:40

    How pharmacist Nikki Holmes helps mental health patients on their journey from high secure services to recovery

    27 NOV 2017 9:36

    Managing risk and protecting patient safety as an internal audit manager for GSK Global

    13 NOV 2017 23:01

    Tech pioneers: pharmacists in technology and software development

    6 NOV 2017 15:37

    Providing medicines information to the masses

    How I balance clinical and managerial support as pharmacy manager for an NHS Treatment Centre

    30 OCT 2017 12:25

    Latest views

    Charting Wales’s progress in professional collaboration and medicines safety

    29 NOV 2017 12:08

    Draft law to lift threat of prosecution for pharmacists

    21 NOV 2017 13:27

    Boost in availability of oral cholera vaccines is a potential game changer in global fight against cholera

    17 NOV 2017 9:55

    Off-label drug use: the need for clear national guidance

    15 NOV 2017 16:28

    Decriminalisation legislation cannot come soon enough

    15 NOV 2017 14:26

    What the Lloyds announcement means for pharmacists

    8 NOV 2017 15:29

    Latest on the RPS

    Pharmacy Research UK awards more than £80k in funding

    30 NOV 2017 15:23

    RPS urges STP leads to include pharmacists in secondary care plans

    30 NOV 2017 11:48

    RPS member Iain Jack captains Ulster University Challenge team

    24 NOV 2017 15:05

    RPS video features pharmacists at work to combat antimicrobial resistance

    24 NOV 2017 14:58

    RPS Scotland tells Scottish Parliament: we need direct access to health records

    24 NOV 2017 9:16

    Scottish Pharmacy Board meeting: 27 September 2017

    17 NOV 2017 14:55

    • You are here: Home
    • News & analysis

    NHS England publishes new prescribing guidance in bid to save millions of pounds

    Independent prescribing by paramedics under consideration

    Pharmacists can be vital part of European healthcare systems, PGEU says

    Pharmaceutical news daily

    NHS England publishes new prescribing guidance in bid to save millions of pounds

    • pause slideshow

    Pharmaceutical news daily

    GPhC members visit UCLan School of Pharmacy

    Members of the General Pharmaceutical Council have visited students at the University of Central Lancashire’s School of Pharmacy in Preston

    Pharmaceutical news daily

    Community pharmacists in Wales to have access to GP records by March 2018

    All pharmacies with access to the Choose Pharmacy IT system in Wales will be able to access the Welsh GP record by March 2018, it was announced at the Royal Pharmaceutical Society Wales Medicines Safety Conference on 29 November 2017

    All Scottish babies should have vitamin D supplement, CMO says

    Scarlet fever in England reaches highest level in 50 years

    Research briefing

    Pharmaceutical news daily

    Insulin pumps lead to better clinical outcomes compared with injection Subscription

    Observational study compared rates of severe hypoglycaemia in diabetes patients using insulin pump and injection therapy.

    Pharmaceutical news daily

    Multivitamins during pregnancy could lower risk of some types of autism Subscription

    Maternal multivitamin use with or without additional iron or folic acid was associated with lower odds of autism spectrum disorder with intellectual disability in the child.

    Pharmaceutical news daily

    Reducing hepatitis C virus transmission Subscription

    Combined needle provision and opioid substitution therapy could cut hepatitis C virus transmission risk.

    Pharmaceutical news daily

    Lack of evidence that cancer drugs approved by the EMA improve survival Subscription

    BMJ published a study investigating the effectiveness of 48 drugs approved by the European Medicines Agency.

    Pharmaceutical news daily

    PPI use not linked to osteoporotic fractures in Barrett’s oesophagus Subscription

    Fractures are not uncommon in patients with the condition, but the rate is not higher than in the general population and is not associated with use of PPIs, researchers concluded.

    Pharmaceutical news daily

    Smoking cessation after myocardial infarction Subscription

    Low adherence to early-use smoking cessation medications after myocardial infarction.

    Features

    Pharmaceutical news daily

    A crisis hidden in plain sight? Prescription opioid misuse in the UK Subscription

    The United States is in the grip of an opioid misuse epidemic, with 142 opioid-related deaths every day. Could prescription painkiller misuse reach crisis levels in the UK too?

    Pharmaceutical news daily

    The crucial role of pharmacists in mental health Subscription

    Pharmacists’ role in mental health is wide ranging and spans different sectors and settings. However, pharmacists often lack confidence in this area. More hands-on experience early in a pharmacist’s training could help build confidence and raise awareness of the specialty as a possible career path.

    Infographics

    Pharmaceutical news daily

    Charting obesity Subscription

    In the UK, the prevalence of obesity is continuing to grow, bringing with it a whole host of hidden diseases affecting a number of body systems — from cardiovascular to skeletal.

    News blog

    Pharmaceutical news daily

    Latest update: Follow news and reaction to pharmacy cuts as they unfold

    Follow the latest updates on the proposed 12% funding cuts to community pharmacy, which could result in the closure of a quarter of pharmacies in England.

    Promotional feature

    Pharmaceutical news daily

    Implementing online fax technology in the pharmacy

    Pharmacies deal with a large volume of patient prescriptions via fax on a daily basis. In order to provide good service and compete with other pharmacies effectively, staff members must be able to process prescriptions quickly and accurately, as well as resolve queries in a timely manner. Unfortunately, this can be a significant issue due to outdated and bulky fax technology that is prone to malfunction, security risks, and unnecessary expenses.





    Welcome to Vanguard Pharmaceutical Machinery, USA, pharmaceutical.#Pharmaceutical

    Pharmaceutical

    PharmaceuticalAutoclaves

    Pharmaceutical Blister Packing

    Pharmaceutical Bottling Packaging Line

    Pharmaceutical Cappers

    Pharmaceutical Capsule Fillers

    PharmaceuticalCapsule Polishers Sorters

    PharmaceuticalCapsule Seperator

    PharmaceuticalCapsule Tablet Printer

    Pharmaceutical Cartoner

    PharmaceuticalCounters

    Pharmaceutical Deblistering Machine

    Pharmaceutical Film Coaters

    Pharmaceutical Fluid-Bed Processors

    Pharmaceutical Granulators

    Pharmaceutical Induction Sealer

    Pharmaceutical Inspection Machines

    PharmaceuticalLab Instruments

    PharmaceuticalLabelers

    Pharmaceutical Liquid Fillers

    PharmaceuticalMixers (V-Shell, IBC. )

    PharmaceuticalPackaging Machines

    PharmaceuticalPharma Handling Equip.

    Pharmaceutical Pharma Ovens

    Pharmaceutical Sifters

    PharmaceuticalSoftgel Manufacturing Line

    Pharmaceutical Tablet Dedusters

    PharmaceuticalTablet Presses

    Pharmaceutical Tube Fillers

    Pharmaceutical

    Pharmaceutical Pharmaceutical

    Pharmaceutical

    Pharmaceutical

    Pharmaceutical





    Mintel: Global Market Research & Market Insight, market research companies.#Market #research #companies

    Welcome to Mintel

    market intelligence agency

    Featured insights

    Fresh perspectives, new data and ground breaking insight into the markets that matter.

    Market research companies

    Industry Specific Solutions

    What you need to know about consumers, markets and innovation, now and in the future.

    These solutions give you access to Mintel’s portfolio of market intelligence:

    Mintel GNPD, Mintel Reports, Mintel Market Sizes and Mintel Trends.

    Market research companies

    Mintel Beauty & Personal Care

    The expert-led global market intelligence solution for the Beauty and Personal Care business.

    Market research companies

    Mintel Food & Drink

    The expert-led global market intelligence solution for the Food and Drink industries.

    Market research companies

    Mintel Household & Personal Care

    The expert-led global market intelligence solution for the Household sector.

    Some of our clients

    We work with more than 5,000 clients worldwide.

    Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies Market research companies

    Mintel Products

    A range of research and insight services available on demand, online.

    Designed to help you grow your business.

    A global database of new product launches in 62 countries, for the consumer packaged goods industry.

    Trend analysis that monitors, tracks and interprets consumer behavior.

    A comprehensive guide to in-depth market analysis and consumer trends in 11 countries.

    Market Size, market share and market forecasts for 34 of the world’s most dynamic markets.

    Competitive intelligence and marketing analysis for direct and digital marketers in North America.

    An all-encompassing viewpoint of foodservice in the US.

    Breakdown of the critical issues facing B2B markets in the United Kingdom.

    Rapid, reliable consumer opinions on every new food and drink product in the US.

    Custom Solutions

    A range of consulting and custom solutions that enable you to answer specific business challenges.

    Market research companies

    Mintel Consulting

    From market assessment to portfolio evaluation, get a fresh viewpoint backed by rigorous data and insight you can trust.

    Market research companies

    Mintel Field Services

    On-the-ground intelligence you need to inform your quality, sales, marketing and product development strategies.

    Latest Insights

    • Market research companies

  • Market research companies

  • Market research companies

  • Market research companies

  • Market research companies

  • Market research companies





  • CMO, biotech, protein manufacturing, microbial fermentation, mammalian, cell banking, contract manufacturing, biopharmaceuticals, cGMP, GMP, biotech

    Biotech: Biologics and cell therapy products

    Biotech pharmaceutical Biotech pharmaceutical

    • Biotech pharmaceutical

    Biotech pharmaceutical

    Biotech pharmaceutical

  • Biotech pharmaceutical

    Biotech pharmaceutical

    Biotech pharmaceutical

  • Biotech pharmaceutical

    Biotech pharmaceutical

    Biotech pharmaceutical

  • Biotech pharmaceutical

    Biotech pharmaceutical

    Biotech pharmaceutical

    Latest News

    COF Navarra 2017 Award

    3P Biopharmaceuticals received last Saturday 25 November the [ ]

    Premio COFNavarra 2017

    3P Biopharmaceuticals recibió el pasado sábado 25 de [ ]

    Innovation